Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Chief Medical Resident, Medicine, Case Western Reserve University 1995 - 1996
  • Fellow in Cardiology, Medicine, U Mass Memorial Medical Center 1986 - 1989
  • Medical Resident, Mecicine, Case Western Reserve University 1982 - 1985
  • M.D., University of Cincinnati 1982
• 

  Duke Appointment History

  • Professor of Medicine, Medicine, Cardiology, Medicine 2004 - 2013
  • Instructor, Temporary in the Department of Medicine, Medicine, Cardiology, Medicine 2003 - 2004
• Recognition
• 

  In the News

  • NOV 19, 2019

    Global List of Highly Cited Puts Duke in Top Ten
• Research
• 

  Selected Grants

  • TRC-THD Administrative Coordinating Center (ACC) awarded by National Institutes of Health 2012 - 2017
  • Responses of Myocardial Ischemia to Sertraline Treatment awarded by National Institutes of Health 2006 - 2013
  • Thrombosis and Hemostasis Centers Research and Prevention Network awarded by Centers for Disease Control and Prevention 2002 - 2013
  • Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin awarded by National Institutes of Health 2009 - 2012
  • Pharmacologic Prevention of Arteriovenous Graft Thrombosis awarded by National Institutes of Health 2007 - 2009
  • Integrated Program for Persons with Hemostatic Disorders awarded by Centers for Disease Control 2001 - 2007
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Boursier, Jérôme, Matthieu Barret, and Anna Mae Diehl. “Reply.” Hepatology 64, no. 3 (September 2016): 994–95. https://doi.org/10.1002/hep.28562.
       Full Text  Link to Item
    • Cox, J., and S. Schwarcz. “Foreword.” Law & Contemporary Problems 78, no. 3 (2015): i–v.
       Open Access Copy  Link to Item
    • Vavalle, J. P., C. P. Rusconi, S. Zelenkofske, W. A. Wargin, T. L. Ortel, J. H. Alexander, T. J. Povsic, and R. C. Becker. “The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.” J Thromb Thrombolysis 38, no. 3 (October 2014): 275–84. https://doi.org/10.1007/s11239-014-1081-6.
       Full Text  Link to Item
    • Welsby, Ian J., Barbara Phillips-Bute, Joseph P. Mathew, Mark F. Newman, Richard Becker, Sunil Rao, Carmelo A. Milano, and Mark Stafford-Smith. “ABO blood group influences transfusion and survival after cardiac surgery.” J Thromb Thrombolysis 38, no. 3 (October 2014): 402–8. https://doi.org/10.1007/s11239-013-1045-2.
       Full Text  Link to Item
    • Piccini, Jonathan P., Jyotsna Garg, Manesh R. Patel, Yuliya Lokhnygina, Shaun G. Goodman, Richard C. Becker, Scott D. Berkowitz, et al. “Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.” Eur Heart J 35, no. 28 (July 21, 2014): 1873–80. https://doi.org/10.1093/eurheartj/ehu083.
       Full Text  Link to Item
    • Halperin, Jonathan L., Graeme J. Hankey, Daniel M. Wojdyla, Jonathan P. Piccini, Yuliya Lokhnygina, Manesh R. Patel, Günter Breithardt, et al. “Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).” Circulation 130, no. 2 (July 8, 2014): 138–46. https://doi.org/10.1161/CIRCULATIONAHA.113.005008.
       Full Text  Link to Item
    • Akerblom, Axel, Niclas Eriksson, Lars Wallentin, Agneta Siegbahn, Bryan J. Barratt, Richard C. Becker, Andrzej Budaj, et al. “Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.” Am Heart J 168, no. 1 (July 2014): 96-102.e2. https://doi.org/10.1016/j.ahj.2014.03.010.
       Full Text  Link to Item
    • Husted, Steen, Stefan K. James, Richard G. Bach, Richard C. Becker, Andrzej Budaj, Magda Heras, Anders Himmelmann, et al. “The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.” Eur Heart J 35, no. 23 (June 14, 2014): 1541–50. https://doi.org/10.1093/eurheartj/ehu075.
       Full Text  Link to Item
    • Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan L. Halperin, Günter Breithardt, Rod Passman, Graeme J. Hankey, et al. “Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.” Heart Rhythm 11, no. 6 (June 2014): 925–32. https://doi.org/10.1016/j.hrthm.2014.03.006.
       Full Text  Link to Item
    • Wong, Ka Sing Lawrence, Dai Yi Hu, Abraham Oomman, Ru-San Tan, Manesh R. Patel, Daniel E. Singer, Günter Breithardt, et al. “Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.” Stroke 45, no. 6 (June 2014): 1739–47. https://doi.org/10.1161/STROKEAHA.113.002968.
       Full Text  Link to Item
    • Voora, Deepak, and Richard C. Becker. “A freeze on tailored antiplatelet therapy?” Circulation 129, no. 21 (May 27, 2014): 2088–90. https://doi.org/10.1161/CIRCULATIONAHA.114.009930.
       Full Text  Link to Item
    • Sherwood, Matthew W., James D. Douketis, Manesh R. Patel, Jonathan P. Piccini, Anne S. Hellkamp, Yuliya Lokhnygina, Alex C. Spyropoulos, et al. “Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).” Circulation 129, no. 18 (May 6, 2014): 1850–59. https://doi.org/10.1161/CIRCULATIONAHA.113.005754.
       Full Text  Link to Item
    • Storey, Robert F., Jayaprakash Kotha, Susan S. Smyth, David J. Moliterno, Tyrus L. Rorick, Tiziano Moccetti, Marco Valgimigli, et al. “Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.” Thromb Haemost 111, no. 5 (May 5, 2014): 883–91. https://doi.org/10.1160/TH13-07-0624.
       Full Text  Link to Item
    • Ahmad, Tariq, and Richard C. Becker. “The unmet need for philanthropic funding of early career cardiovascular investigators.” J Thromb Thrombolysis 37, no. 4 (May 2014): 527–31. https://doi.org/10.1007/s11239-013-1016-7.
       Full Text  Link to Item
    • Hankey, Graeme J., Susanna R. Stevens, Jonathan P. Piccini, Yuliya Lokhnygina, Kenneth W. Mahaffey, Jonathan L. Halperin, Manesh R. Patel, et al. “Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.” Stroke 45, no. 5 (May 2014): 1304–12. https://doi.org/10.1161/STROKEAHA.113.004506.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Claes Held, Daniel M. Wojdyla, Stefan K. James, Hugo A. Katus, Steen Husted, Philippe Gabriel Steg, et al. “Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.” J Am Coll Cardiol 63, no. 15 (April 22, 2014): 1493–99. https://doi.org/10.1016/j.jacc.2014.01.038.
       Full Text  Link to Item
    • Jackson, Larry R., and Richard C. Becker. “Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.” J Thromb Thrombolysis 37, no. 3 (April 2014): 380–91. https://doi.org/10.1007/s11239-013-0958-0.
       Full Text  Link to Item
    • Goodman, Shaun G., Daniel M. Wojdyla, Jonathan P. Piccini, Harvey D. White, John F. Paolini, Christopher C. Nessel, Scott D. Berkowitz, et al. “Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).” J Am Coll Cardiol 63, no. 9 (March 11, 2014): 891–900. https://doi.org/10.1016/j.jacc.2013.11.013.
       Full Text  Link to Item
    • Abo-Salem, E., and R. Becker. “Transitioning to and from the novel oral anticoagulants: A management strategy for clinicians.” Journal of Thrombosis and Thrombolysis 37, no. 3 (2014): 372–79. https://doi.org/10.1007/s11239-014-1060-y.
       Full Text
    • Becker, R. C. “Editor's page.” Journal of Thrombosis and Thrombolysis 37, no. 2 (2014): 216-. https://doi.org/10.1007/s11239-014-1051-z.
       Full Text
    • Daly, P. L., and R. C. Becker. “Pharmacogenetics of antiplatelet therapy.” Current Atherosclerosis Reports 16, no. 5 (2014). https://doi.org/10.1007/s11883-014-0411-7.
       Full Text
    • DeWald, Tracy A., and Richard C. Becker. “The pharmacology of novel oral anticoagulants.” J Thromb Thrombolysis 37, no. 2 (2014): 217–33. https://doi.org/10.1007/s11239-013-0967-z.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Susanna R. Stevens, Harvey D. White, Christopher C. Nessel, Shaun G. Goodman, Jonathan P. Piccini, Manesh R. Patel, et al. “Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.” Eur Heart J 35, no. 4 (January 2014): 233–41. https://doi.org/10.1093/eurheartj/eht428.
       Full Text  Link to Item
    • Steinberg, Benjamin A., and Richard C. Becker. “Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.” J Thromb Thrombolysis 37, no. 2 (2014): 234–41. https://doi.org/10.1007/s11239-013-0991-z.
       Full Text  Link to Item
    • Steinhubl, S. R., J. W. Eikelboom, E. M. Hylek, H. L. Dauerman, S. S. Smyth, and R. C. Becker. “Antiplatelet therapy in prevention of cardio- and venous thromboembolic events.” Journal of Thrombosis and Thrombolysis 37, no. 3 (2014): 362–71. https://doi.org/10.1007/s11239-013-1023-8.
       Full Text
    • Swigris, Jeffrey J., David L. Streiner, Kevin K. Brown, Amanda Belkin, Kathy E. Green, Frederick S. Wamboldt, and Frederick S. IPFnet Investigators. “Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.” Respir Med 108, no. 1 (January 2014): 181–88. https://doi.org/10.1016/j.rmed.2013.12.009.
       Full Text  Link to Item
    • Wallentin, Lars, Richard C. Becker, Christopher P. Cannon, Claes Held, Anders Himmelmann, Steen Husted, Stefan K. James, et al. “Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013.” Int J Cardiol 170, no. 3 (January 1, 2014): e59–62. https://doi.org/10.1016/j.ijcard.2013.11.003.
       Full Text  Link to Item
    • Wisler, James W., and Richard C. Becker. “Emerging paradigms in arterial thrombosis.” J Thromb Thrombolysis 37, no. 1 (January 2014): 4–11. https://doi.org/10.1007/s11239-013-0965-1.
       Full Text  Link to Item
    • Rodés-Cabau, Josep, Harold L. Dauerman, Mauricio G. Cohen, Roxana Mehran, Eric M. Small, Susan S. Smyth, Marco A. Costa, et al. “Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events.” J Am Coll Cardiol 62, no. 25 (December 24, 2013): 2349–59. https://doi.org/10.1016/j.jacc.2013.03.029.
       Full Text  Link to Item
    • Tantry, Udaya S., Laurent Bonello, Daniel Aradi, Matthew J. Price, Young-Hoon Jeong, Dominick J. Angiolillo, Gregg W. Stone, et al. “Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.” J Am Coll Cardiol 62, no. 24 (December 17, 2013): 2261–73. https://doi.org/10.1016/j.jacc.2013.07.101.
       Full Text  Link to Item
    • Becker, R. C., M. Y. Chan, J. P. Vavalle, and T. J. Povsic. “Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor.” Drug Development Research 74, no. 8 (December 1, 2013): 510–16. https://doi.org/10.1002/ddr.21109.
       Full Text
    • Xu, Weixian, Dajuanicia N. Holmes, Richard C. Becker, Matthew T. Roe, Eric D. Peterson, and Tracy Y. Wang. “Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database.” Am Heart J 166, no. 6 (December 2013): 1050–55. https://doi.org/10.1016/j.ahj.2013.10.001.
       Full Text  Link to Item
    • Bernacki, Gwen M., and Richard C. Becker. “Oral anticoagulants in older adults with atrial fibrillation.” J Thromb Thrombolysis 36, no. 4 (November 2013): 403–15. https://doi.org/10.1007/s11239-013-0869-0.
       Full Text  Link to Item
    • Boyle, Stephen H., Zainab Samad, Richard C. Becker, Redford Williams, Cynthia Kuhn, Thomas L. Ortel, Maragatha Kuchibhatla, et al. “Depressive symptoms and mental stress-induced myocardial ischemia in patients with coronary heart disease.” Psychosom Med 75, no. 9 (November 2013): 822–31. https://doi.org/10.1097/PSY.0b013e3182a893ae.
       Full Text  Link to Item
    • Mentz, Robert J., and Richard C. Becker. “Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research.” J Thromb Thrombolysis 36, no. 4 (November 2013): 527–32. https://doi.org/10.1007/s11239-013-0970-4.
       Full Text  Link to Item
    • Vavalle, John P., Thomas J. Povsic, Laura H. Aberle, Steven L. Zelenkofske, Roxana Mehran, Jaroslaw D. Kasprzak, Christoph Bode, et al. “Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial.” J Invasive Cardiol 25, no. 11 (November 2013): 593–99.
       Link to Item
    • Voora, Deepak, Derek Cyr, Joseph Lucas, Jen-Tsan Chi, Jennifer Dungan, Timothy A. McCaffrey, Richard Katz, et al. “Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.” J Am Coll Cardiol 62, no. 14 (October 1, 2013): 1267–76. https://doi.org/10.1016/j.jacc.2013.05.073.
       Full Text  Link to Item
    • Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, Daniel E. Singer, Yuliya Lokhnygina, Alan S. Go, Manesh R. Patel, et al. “Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".” Circulation 128, no. 11 (September 10, 2013): e172–73. https://doi.org/10.1161/CIRCULATIONAHA.113.004013.
       Full Text  Link to Item
    • Åkerblom, Axel, Lars Wallentin, Anders Larsson, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Anders Himmelmann, et al. “Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.” Clin Chem 59, no. 9 (September 2013): 1369–75. https://doi.org/10.1373/clinchem.2012.200709.
       Full Text  Link to Item
    • Becker, R. C., D. Voora, and S. H. Shah. “Hemostasis and Thrombosis” 2 (August 29, 2013): 602–11. https://doi.org/10.1016/B978-0-12-382227-7.00052-5.
       Full Text
    • James, Stefan K., Robert F. Storey, Karen S. Pieper, Christopher P. Cannon, Richard C. Becker, Philippe Gabriel Steg, Lars Wallentin, Robert A. Harrington, and Robert A. PLATO Study Group. “Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".” Stroke 44, no. 8 (August 2013): e95–96. https://doi.org/10.1161/STROKEAHA.113.002069.
       Full Text  Link to Item
    • Pokorney, Sean D., Matthew W. Sherwood, and Richard C. Becker. “Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation.” J Thromb Thrombolysis 36, no. 2 (August 2013): 163–74. https://doi.org/10.1007/s11239-013-0956-2.
       Full Text  Link to Item
    • Povsic, Thomas J., John P. Vavalle, Laura H. Aberle, Jaroslaw D. Kasprzak, Mauricio G. Cohen, Roxana Mehran, Christoph Bode, et al. “A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.” Eur Heart J 34, no. 31 (August 2013): 2481–89. https://doi.org/10.1093/eurheartj/ehs232.
       Full Text  Link to Item
    • Collard, Harold R., Eric Yow, Luca Richeldi, Kevin J. Anstrom, Craig Glazer, and Craig IPFnet investigators. “Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.” Respir Res 14 (July 13, 2013): 73. https://doi.org/10.1186/1465-9921-14-73.
       Full Text  Link to Item
    • Doll, Jacob, Emily Zeitler, and Richard Becker. “Generic clopidogrel: time to substitute?” Jama 310, no. 2 (July 10, 2013): 145–46. https://doi.org/10.1001/jama.2013.7155.
       Full Text  Link to Item
    • Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, Richard C. Becker, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, et al. “Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.” Circ Heart Fail 6, no. 4 (July 2013): 740–47. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000212.
       Full Text  Link to Item
    • Lopes, Renato D., Richard C. Becker, L Kristin Newby, Eric D. Peterson, Elaine M. Hylek, Robert Giugliano, Christopher B. Granger, et al. “Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil.” J Thromb Thrombolysis 36, no. 1 (July 2013): 115–30. https://doi.org/10.1007/s11239-013-0906-z.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Anne S. Hellkamp, Manesh R. Patel, Karen L. Hannan, Kimberly Schwabe, Christopher C. Nessel, Scott D. Berkowitz, et al. “End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.” Circ Cardiovasc Qual Outcomes 6, no. 4 (July 2013): 470–78. https://doi.org/10.1161/CIRCOUTCOMES.113.000132.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Daniel Wojdyla, Graeme J. Hankey, Harvey D. White, Christopher C. Nessel, Jonathan P. Piccini, Manesh R. Patel, et al. “Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.” Ann Intern Med 158, no. 12 (June 18, 2013): 861–68. https://doi.org/10.7326/0003-4819-158-12-201306180-00003.
       Full Text  Link to Item
    • Jiang, Wei, Eric J. Velazquez, Maragatha Kuchibhatla, Zainab Samad, Stephen H. Boyle, Cynthia Kuhn, Richard C. Becker, et al. “Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.” Jama 309, no. 20 (May 22, 2013): 2139–49. https://doi.org/10.1001/jama.2013.5566.
       Full Text  Link to Item
    • Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, Manesh R. Patel, Jonathan L. Halperin, Daniel E. Singer, Graeme J. Hankey, et al. “Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.” J Am Coll Cardiol 61, no. 19 (May 14, 2013): 1998–2006. https://doi.org/10.1016/j.jacc.2013.02.025.
       Full Text  Link to Item
    • James, Stefan K., Karen S. Pieper, Christopher P. Cannon, Robert F. Storey, Richard C. Becker, Philippe Gabriel Steg, Lars Wallentin, Robert A. Harrington, and Robert A. PLATO study group. “Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.” Stroke 44, no. 5 (May 2013): 1477–79. https://doi.org/10.1161/STROKEAHA.111.000514.
       Full Text  Link to Item
    • Jiang, Wei, Zainab Samad, Stephen Boyle, Richard C. Becker, Redford Williams, Cynthia Kuhn, Thomas L. Ortel, et al. “Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease.” J Am Coll Cardiol 61, no. 7 (February 19, 2013): 714–22. https://doi.org/10.1016/j.jacc.2012.11.037.
       Full Text  Link to Item
    • Singer, Daniel E., Anne S. Hellkamp, Jonathan P. Piccini, Kenneth W. Mahaffey, Yuliya Lokhnygina, Guohua Pan, Jonathan L. Halperin, et al. “Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.” J Am Heart Assoc 2, no. 1 (February 19, 2013): e000067. https://doi.org/10.1161/JAHA.112.000067.
       Full Text  Link to Item
    • Becker, Richard C. “A thought experiment in contemporary drug development: informed bench-to-bedside strategies.” J Am Heart Assoc 2, no. 1 (February 12, 2013): e000031. https://doi.org/10.1161/JAHA.112.000031.
       Full Text  Link to Item
    • Patel, Manesh R., Anne S. Hellkamp, Yuliya Lokhnygina, Jonathan P. Piccini, Zhongxin Zhang, Surya Mohanty, Daniel E. Singer, et al. “Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).” J Am Coll Cardiol 61, no. 6 (February 12, 2013): 651–58. https://doi.org/10.1016/j.jacc.2012.09.057.
       Full Text  Link to Item
    • Piccini, Jonathan P., Susanna R. Stevens, YuChiao Chang, Daniel E. Singer, Yuliya Lokhnygina, Alan S. Go, Manesh R. Patel, et al. “Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.” Circulation 127, no. 2 (January 15, 2013): 224–32. https://doi.org/10.1161/CIRCULATIONAHA.112.107128.
       Full Text  Link to Item
    • Becker, R. C., M. Y. Chan, J. P. Vavalle, and T. J. Povsic. “Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor.” Drug Development Research, 2013.
    • Berger, Jeffrey S., Richard C. Becker, Cynthia Kuhn, Michael J. Helms, Thomas L. Ortel, and Redford Williams. “Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.” Thromb Haemost 109, no. 1 (January 2013): 85–92. https://doi.org/10.1160/TH12-03-0202.
       Full Text  Link to Item
    • Brummett, Beverly H., Michael A. Babyak, Rong Jiang, Svati H. Shah, Richard C. Becker, Carol Haynes, Megan Chryst-Ladd, et al. “A functional polymorphism in the 5HTR2C gene associated with stress responses also predicts incident cardiovascular events.” Plos One 8, no. 12 (2013): e82781. https://doi.org/10.1371/journal.pone.0082781.
       Full Text  Open Access Copy  Link to Item
    • Krishnan, Anandi, Erwin A. Vogler, Bruce A. Sullenger, and Richard C. Becker. “The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.” J Thromb Thrombolysis 35, no. 1 (January 2013): 48–56. https://doi.org/10.1007/s11239-012-0778-7.
       Full Text  Link to Item
    • Vemulapalli, S., and R. C. Becker. “Hemostatic Aspects of Cardiovascular Medicine,” January 1, 2013, 342–94. https://doi.org/10.1016/B978-1-4557-2296-9.00021-X.
       Full Text
    • Wallentin, L., D. Lindholm, A. Siegbahn, L. Wernroth, R. C. Becker, C. P. Cannon, J. H. Cornel, et al. “Biomarkers in relation to the effects of ticagrelor compared with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: A substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) trial.” Circulation, 2013. https://doi.org/10.1161/CIRCULATIONAHA.113.004420.
       Full Text
    • Chan, Mark Y., Min Lin, Joseph Lucas, Arthur Moseley, J Will Thompson, Derek Cyr, Hitoshi Ueda, Mariko Kajikawa, Thomas L. Ortel, and Richard C. Becker. “Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.” Thromb Haemost 108, no. 6 (December 2012): 1180–91. https://doi.org/10.1160/TH12-05-0310.
       Full Text  Link to Item
    • Akerblom, Axel, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Jay Horrow, Steen Husted, et al. “Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.” Am Heart J 164, no. 5 (November 2012): 728–34. https://doi.org/10.1016/j.ahj.2012.08.017.
       Full Text  Link to Item
    • Hess, Connie N., Richard C. Becker, John H. Alexander, and Renato D. Lopes. “Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.” J Thromb Thrombolysis 34, no. 4 (November 2012): 552–61. https://doi.org/10.1007/s11239-012-0785-8.
       Full Text  Link to Item
    • Patel, C. B., J. Suarez, G. M. Felker, R. Becker, A. F. Hernandez, and J. G. Rogers. “Response to letter regarding article, mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices.” Circulation: Heart Failure 5, no. 6 (November 1, 2012). https://doi.org/10.1161/CIRCHEARTFAILURE.112.971283.
       Full Text
    • Prystowsky, Eric N. “Electrophysiology in China: a special supplement. Introduction.” J Cardiovasc Electrophysiol 23 Suppl 1 (November 2012): S1. https://doi.org/10.1111/jce.12010.
       Full Text  Link to Item
    • Varenhorst, Christoph, Ulrica Alström, Benjamin M. Scirica, Charles W. Hogue, Nils Åsenblad, Robert F. Storey, Ph Gabriel Steg, et al. “Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.” J Am Coll Cardiol 60, no. 17 (October 23, 2012): 1623–30. https://doi.org/10.1016/j.jacc.2012.07.021.
       Full Text  Link to Item
    • Cornel, Jan H., Richard C. Becker, Shaun G. Goodman, Steen Husted, Hugo Katus, Anwar Santoso, Gabriel Steg, et al. “Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.” Am Heart J 164, no. 3 (September 2012): 334-342.e1. https://doi.org/10.1016/j.ahj.2012.06.005.
       Full Text  Link to Item
    • Husted, Steen, Stefan James, Richard C. Becker, Jay Horrow, Hugo Katus, Robert F. Storey, Christopher P. Cannon, et al. “Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.” Circ Cardiovasc Qual Outcomes 5, no. 5 (September 1, 2012): 680–88. https://doi.org/10.1161/CIRCOUTCOMES.111.964395.
       Full Text  Link to Item
    • Bompiani, K. M., R. S. Woodruff, R. C. Becker, S. M. Nimjee, and B. A. Sullenger. “Antidote control of aptamer therapeutics: the road to a safer class of drug agents.” Curr Pharm Biotechnol 13, no. 10 (August 2012): 1924–34. https://doi.org/10.2174/138920112802273137.
       Full Text  Link to Item
    • Angiolillo, Dominick J., David J. Schneider, Deepak L. Bhatt, William J. French, Matthew J. Price, Jorge F. Saucedo, Tamaz Shaburishvili, et al. “Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.” J Thromb Thrombolysis 34, no. 1 (July 2012): 44–55. https://doi.org/10.1007/s11239-012-0737-3.
       Full Text  Link to Item
    • Becker, Richard C., and Susan Smyth. “Biomarker science: on a theme of personalized medicine.” J Thromb Thrombolysis 34, no. 1 (July 2012): 141–42. https://doi.org/10.1007/s11239-012-0726-6.
       Full Text  Link to Item
    • Berger, Jeffrey S., Peter M. Herout, Qing Harshaw, Steven R. Steinhubl, Carla B. Frye, and Richard C. Becker. “Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.” J Thromb Thrombolysis 34, no. 1 (July 2012): 56–64. https://doi.org/10.1007/s11239-012-0694-x.
       Full Text  Link to Item
    • Harrison, Robert W., Thomas L. Ortel, and Richard C. Becker. “To bridge or not to bridge: these are the questions.” J Thromb Thrombolysis 34, no. 1 (July 2012): 31–35. https://doi.org/10.1007/s11239-012-0732-8.
       Full Text  Link to Item
    • Lopes, Renato D., Richard C. Becker, L Kristin Newby, Eric D. Peterson, Elaine M. Hylek, Christopher B. Granger, Mark Crowther, et al. “Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.” J Thromb Thrombolysis 34, no. 1 (July 2012): 143–63. https://doi.org/10.1007/s11239-012-0700-3.
       Full Text  Link to Item
    • Thomas, Michael P., Kenneth W. Mahaffey, Karen Chiswell, Marc Cohen, Michael C. Kontos, Elliott M. Antman, James J. Ferguson, Robert M. Califf, Shaun G. Goodman, and Richard C. Becker. “Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.” J Thromb Thrombolysis 34, no. 1 (July 2012): 114–19. https://doi.org/10.1007/s11239-012-0693-y.
       Full Text  Link to Item
    • Vavalle, J. P., C. P. Rusconi, S. Zelenkofske, W. A. Wargin, J. H. Alexander, and R. C. Becker. “A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.” J Thromb Haemost 10, no. 7 (July 2012): 1303–11. https://doi.org/10.1111/j.1538-7836.2012.04742.x.
       Full Text  Link to Item
    • James, Stefan K., Robert F. Storey, Nardev S. Khurmi, Steen Husted, Matyas Keltai, Kenneth W. Mahaffey, Juan Maya, et al. “Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.” Circulation 125, no. 23 (June 12, 2012): 2914–21. https://doi.org/10.1161/CIRCULATIONAHA.111.082727.
       Full Text  Link to Item
    • Wisler, James W., and Richard C. Becker. “A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.” Crit Pathw Cardiol 11, no. 2 (June 2012): 55–61. https://doi.org/10.1097/HPC.0b013e31825298ef.
       Full Text  Link to Item
    • Becker, Richard C. “Aspirin and the prevention of venous thromboembolism.” N Engl J Med 366, no. 21 (May 24, 2012): 2028–30. https://doi.org/10.1056/NEJMe1201911.
       Full Text  Link to Item
    • Chan, Mark Y., Karen Tan, Huay-Cheem Tan, Pei-Tee Huan, Bei Li, Qian-Hui Phua, Hong-Kai Lee, et al. “CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.” Pharmacogenomics 13, no. 5 (April 2012): 533–42. https://doi.org/10.2217/pgs.12.24.
       Full Text  Link to Item
    • Hankey, Graeme J., Manesh R. Patel, Susanna R. Stevens, Richard C. Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, et al. “Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.” Lancet Neurol 11, no. 4 (April 2012): 315–22. https://doi.org/10.1016/S1474-4422(12)70042-X.
       Full Text  Link to Item
    • Rowley, Jesse W., Aloke V. Finn, Patricia A. French, Lisa K. Jennings, Danny Bluestein, Peter L. Gross, Jane E. Freedman, et al. “Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.” Circ Cardiovasc Interv 5, no. 2 (April 2012): 296–304. https://doi.org/10.1161/CIRCINTERVENTIONS.111.965426.
       Full Text  Link to Item
    • Voora, Deepak, Thomas L. Ortel, Joseph E. Lucas, Jen-Tsan Chi, Richard C. Becker, and Geoffrey S. Ginsburg. “Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.” J Thromb Thrombolysis 33, no. 3 (April 2012): 246–57. https://doi.org/10.1007/s11239-012-0683-0.
       Full Text  Link to Item
    • Wisler, James W., Jeffrey B. Washam, and Richard C. Becker. “Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.” J Thromb Thrombolysis 33, no. 3 (April 2012): 287–95. https://doi.org/10.1007/s11239-011-0677-3.
       Full Text  Link to Item
    • Wang, Tracy Y., Dominick J. Angiolillo, Mary Cushman, Marc S. Sabatine, Paul F. Bray, Susan S. Smyth, Harold L. Dauerman, Patricia A. French, and Richard C. Becker. “Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.” J Am Coll Cardiol 59, no. 10 (March 6, 2012): 891–900. https://doi.org/10.1016/j.jacc.2011.09.075.
       Full Text  Link to Item
    • Wisler, James W., and Richard C. Becker. “Oral factor Xa inhibitors for the long-term management of ACS.” Nat Rev Cardiol 9, no. 7 (February 21, 2012): 392–401. https://doi.org/10.1038/nrcardio.2012.18.
       Full Text  Link to Item
    • Becker, R. C. “Elite reviewers 2011.” Journal of Thrombosis and Thrombolysis 33, no. 2 (February 1, 2012): 209. https://doi.org/10.1007/s11239-011-0666-6.
       Full Text
    • Nimjee, Shahid M., Jens D. Lohrmann, Haichen Wang, David J. Snyder, Thomas J. Cummings, Richard C. Becker, Sabah Oney, and Bruce A. Sullenger. “Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.” Mol Ther 20, no. 2 (February 2012): 391–97. https://doi.org/10.1038/mt.2011.226.
       Full Text  Link to Item
    • Akerblom, Åxel, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Kristen Buck, Evangelos Giannitsis, et al. “Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.” Clin Chem 58, no. 1 (January 2012): 190–99. https://doi.org/10.1373/clinchem.2011.171520.
       Full Text  Link to Item
    • Jiang, Wei, Eric J. Velazquez, Zainab Samad, Maragatha Kuchibhatla, Carolyn Martsberger, Joseph Rogers, Redford Williams, et al. “Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.” Am Heart J 163, no. 1 (January 2012): 20–26. https://doi.org/10.1016/j.ahj.2011.09.018.
       Full Text  Link to Item
    • Leonardi, Sergio, Pierluigi Tricoci, and Richard C. Becker. “Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.” Adv Cardiol 47 (2012): 87–99. https://doi.org/10.1159/000338045.
       Full Text  Link to Item
    • Leonardi, Sergio, and Richard C. Becker. “PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.” Handb Exp Pharmacol, no. 210 (2012): 239–60. https://doi.org/10.1007/978-3-642-29423-5_10.
       Full Text  Link to Item
    • Becker, Richard C., Jean Pierre Bassand, Andrzej Budaj, Daniel M. Wojdyla, Stefan K. James, Jan H. Cornel, John French, et al. “Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.” Eur Heart J 32, no. 23 (December 2011): 2933–44. https://doi.org/10.1093/eurheartj/ehr422.
       Full Text  Link to Item
    • Granada, Juan F., Matthew J. Price, Patricia A. French, Steven R. Steinhubl, Donald E. Cutlip, Richard C. Becker, Susan S. Smyth, and Harold L. Dauerman. “Platelet-mediated thrombosis and drug-eluting stents.” Circ Cardiovasc Interv 4, no. 6 (December 1, 2011): 629–37. https://doi.org/10.1161/CIRCINTERVENTIONS.111.964635.
       Full Text  Link to Item
    • Piccini, Jonathan P., Thomas W. Wallace, Manesh R. Patel, and Richard C. Becker. “Stroke prevention in atrial fibrillation.” Cardiovasc Drugs Ther 25, no. 6 (December 2011): 561–70. https://doi.org/10.1007/s10557-011-6334-4.
       Full Text  Link to Item
    • Storey, Robert F., Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan K. James, Frank Cools, Philippe Gabriel Steg, et al. “Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).” Am J Cardiol 108, no. 11 (December 1, 2011): 1542–46. https://doi.org/10.1016/j.amjcard.2011.07.015.
       Full Text  Link to Item
    • Storey, Robert F., Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan K. James, Frank Cools, Philippe Gabriel Steg, et al. “Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.” Eur Heart J 32, no. 23 (December 2011): 2945–53. https://doi.org/10.1093/eurheartj/ehr231.
       Full Text  Link to Item
    • Suarez, Jorge, Chetan B. Patel, G Michael Felker, Richard Becker, Adrian F. Hernandez, and Joseph G. Rogers. “Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices.” Circ Heart Fail 4, no. 6 (November 2011): 779–84. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962613.
       Full Text  Link to Item
    • Faxon, David P., John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, David J. Moliterno, Richard C. Becker, and Dominick J. Angiolillo. “Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective.” Thromb Haemost 106, no. 4 (October 2011): 572–84. https://doi.org/10.1160/TH11-04-0262.
       Full Text  Link to Item
    • Faxon, David P., John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, David J. Moliterno, Richard C. Becker, and Dominick J. Angiolillo. “Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary.” Circ Cardiovasc Interv 4, no. 5 (October 1, 2011): 522–34. https://doi.org/10.1161/CIRCINTERVENTIONS.111.965186.
       Full Text  Link to Item
    • Fox, Keith A. A., Jonathan P. Piccini, Daniel Wojdyla, Richard C. Becker, Jonathan L. Halperin, Christopher C. Nessel, John F. Paolini, et al. “Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.” Eur Heart J 32, no. 19 (October 2011): 2387–94. https://doi.org/10.1093/eurheartj/ehr342.
       Full Text  Link to Item
    • Povsic, Thomas J., William A. Wargin, John H. Alexander, Joshua Krasnow, Merill Krolick, Mauricio G. Cohen, Roxana Mehran, et al. “Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.” Eur Heart J 32, no. 19 (October 2011): 2412–19. https://doi.org/10.1093/eurheartj/ehr179.
       Full Text  Link to Item
    • Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E. Singer, Werner Hacke, Günter Breithardt, et al. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.” N Engl J Med 365, no. 10 (September 8, 2011): 883–91. https://doi.org/10.1056/NEJMoa1009638.
       Full Text  Link to Item
    • Ahmad, Tariq, Deepak Voora, and Richard C. Becker. “The pharmacogenetics of antiplatelet agents: towards personalized therapy?” Nat Rev Cardiol 8, no. 10 (August 9, 2011): 560–71. https://doi.org/10.1038/nrcardio.2011.111.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Daniel M. Wojdyla, Kevin Carroll, Richard C. Becker, Robert F. Storey, Dominick J. Angiolillo, Claes Held, et al. “Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.” Circulation 124, no. 5 (August 2, 2011): 544–54. https://doi.org/10.1161/CIRCULATIONAHA.111.047498.
       Full Text  Link to Item
    • Becker, Richard C., Hongqiu Yang, Yuchen Barrett, Puneet Mohan, Jessie Wang, Lars Wallentin, and John H. Alexander. “Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.” J Thromb Thrombolysis 32, no. 2 (August 2011): 183–87. https://doi.org/10.1007/s11239-011-0591-8.
       Full Text  Link to Item
    • Lopes, Renato D., Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, et al. “Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.” J Thromb Thrombolysis 32, no. 2 (August 2011): 242–66. https://doi.org/10.1007/s11239-011-0592-7.
       Full Text  Link to Item
    • Roser-Jones, Christopher, Mark Chan, Emily L. Howard, Kristian C. D. Becker, Christopher P. Rusconi, and Richard C. Becker. “Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.” Cardiovasc Ther 29, no. 4 (August 2011): e22–35. https://doi.org/10.1111/j.1755-5922.2010.00134.x.
       Full Text  Link to Item
    • Ramanujam, N., and J. Popp. “Introduction.” Progress in Biomedical Optics and Imaging  Proceedings of Spie 8087 (July 25, 2011).
    • Becker, Richard C. “Early-onset obesity and the unwanted promise of thrombosis.” J Thromb Thrombolysis 32, no. 1 (July 2011): 125–28. https://doi.org/10.1007/s11239-011-0575-8.
       Full Text  Link to Item
    • Newby, L Kristin, Ignacio Rodriguez, John Finkle, Richard C. Becker, Karen A. Hicks, Elizabeth Hausner, Ruth Chesler, et al. “Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration.” Am Heart J 162, no. 1 (July 2011): 64–73. https://doi.org/10.1016/j.ahj.2011.04.005.
       Full Text  Link to Item
    • Povsic, T. J., M. G. Cohen, M. Y. Chan, S. L. Zelenkofske, W. A. Wargin, R. A. Harrington, J. H. Alexander, C. P. Rusconi, and R. C. Becker. “Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.” J Thromb Thrombolysis 32, no. 1 (July 2011): 21–31. https://doi.org/10.1007/s11239-011-0588-3.
       Full Text  Link to Item
    • Woodruff, Rebecca S., Bruce Sullenger, and Richard C. Becker. “The many faces of the contact pathway and their role in thrombosis.” J Thromb Thrombolysis 32, no. 1 (July 2011): 9–20. https://doi.org/10.1007/s11239-011-0578-5.
       Full Text  Link to Item
    • Xu, Weixian, Tracy Y. Wang, and Richard C. Becker. “[Hematologic diseases: from within the heart].” Rev Esp Cardiol 64, no. 7 (July 2011): 606–13. https://doi.org/10.1016/j.recesp.2011.02.018.
       Full Text  Link to Item
    • Bettari, Luca, Mona Fiuzat, Richard Becker, G Michael Felker, Marco Metra, and Christopher M. O’Connor. “Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.” Circ Heart Fail 4, no. 3 (May 2011): 361–68. https://doi.org/10.1161/CIRCHEARTFAILURE.110.959957.
       Full Text  Link to Item
    • Wallentin, L., R. C. Becker, S. K. James, and R. A. Harrington. “The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).” Thromb Haemost 105, no. 5 (May 2011): 760–62. https://doi.org/10.1160/TH11-03-0162.
       Full Text  Link to Item
    • Katz, Jason N., Kamalkumar P. Kolappa, and Richard C. Becker. “Beyond thrombosis: the versatile platelet in critical illness.” Chest 139, no. 3 (March 2011): 658–68. https://doi.org/10.1378/chest.10-1971.
       Full Text  Link to Item
    • Held, Claes, Nils Asenblad, Jean Pierre Bassand, Richard C. Becker, Christopher P. Cannon, Marc J. Claeys, Robert A. Harrington, et al. “Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.” J Am Coll Cardiol 57, no. 6 (February 8, 2011): 672–84. https://doi.org/10.1016/j.jacc.2010.10.029.
       Full Text  Link to Item
    • Becker, Richard C., Kenneth W. Mahaffey, Hongqiu Yang, A. J. Marian, Mark I. Furman, A. Michael Lincoff, Stanley L. Hazen, et al. “Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.” J Thromb Thrombolysis 31, no. 2 (February 2011): 146–53. https://doi.org/10.1007/s11239-010-0532-y.
       Full Text  Link to Item
    • Povsic, Thomas J., Mauricio G. Cohen, Roxana Mehran, Christopher E. Buller, Christoph Bode, Jan H. Cornel, Jarosław D. Kasprzak, et al. “A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.” Am Heart J 161, no. 2 (February 2011): 261-268.e1-2. https://doi.org/10.1016/j.ahj.2010.10.022.
       Full Text  Link to Item
    • Sherwood, Matthew W., Tracy Y. Wang, and Richard C. Becker. “How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?” Curr Treat Options Cardiovasc Med 13, no. 1 (February 2011): 46–56. https://doi.org/10.1007/s11936-010-0107-4.
       Full Text  Link to Item
    • Ahmad, T., D. Voora, and R. C. Becker. “The pharmacogenetics of antiplatelet agents: towards personalized therapy?” Nature Reviews Cardiology, 2011.
    • Becker, R. C., and F. Andreotti. “Genetics and Genomics in the Management of Hemostasis and Thrombosis,” December 1, 2010, 374–89. https://doi.org/10.1016/B978-0-12-374934-5.00030-1.
       Full Text
    • Katz, J. N., and R. C. Becker. “Evolution of the Coronary Care Unit: Past, Present, and Future,” December 1, 2010, 1–8. https://doi.org/10.1016/B978-1-4160-3773-6.10001-1.
       Full Text
    • Povsic, Thomas J., Bruce A. Sullenger, Steven L. Zelenkofske, Christopher P. Rusconi, and Richard C. Becker. “Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.” J Cardiovasc Transl Res 3, no. 6 (December 2010): 704–16. https://doi.org/10.1007/s12265-010-9230-6.
       Full Text  Link to Item
    • Williams, Marlene S., Ethan J. Weiss, Marc S. Sabatine, Daniel I. Simon, Wadie F. Bahou, Lewis C. Becker, Leslie V. Parise, et al. “Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.” Arterioscler Thromb Vasc Biol 30, no. 12 (December 2010): 2372–84. https://doi.org/10.1161/ATVBAHA.110.218131.
       Full Text  Link to Item
    • Steg, Philippe Gabriel, Stefan James, Robert A. Harrington, Diego Ardissino, Richard C. Becker, Christopher P. Cannon, Håkan Emanuelsson, et al. “Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.” Circulation 122, no. 21 (November 23, 2010): 2131–41. https://doi.org/10.1161/CIRCULATIONAHA.109.927582.
       Full Text  Link to Item
    • Becker, Richard C. “A time-tested ex vivo model of thrombosis: from pathophysiology to drug development and disease application.” Thromb Res 126, no. 5 (November 2010): 363–64. https://doi.org/10.1016/j.thromres.2010.08.023.
       Full Text  Link to Item
    • Becker, Richard C., John H. Alexander, L Kristin Newby, Hongqiu Yang, Yuchen Barrett, Puneet Mohan, Jessie Wang, Robert A. Harrington, and Lars C. Wallentin. “Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.” Thromb Haemost 104, no. 5 (November 2010): 976–83. https://doi.org/10.1160/TH10-04-0247.
       Full Text  Link to Item
    • Storey, Robert F., Dominick J. Angiolillo, Shankar B. Patil, Bhaloo Desai, Rosemary Ecob, Steen Husted, Hakan Emanuelsson, Christopher P. Cannon, Richard C. Becker, and Lars Wallentin. “Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.” J Am Coll Cardiol 56, no. 18 (October 26, 2010): 1456–62. https://doi.org/10.1016/j.jacc.2010.03.100.
       Full Text  Link to Item
    • Wallentin, Lars, Stefan James, Robert F. Storey, Martin Armstrong, Bryan J. Barratt, Jay Horrow, Steen Husted, et al. “Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.” Lancet 376, no. 9749 (October 16, 2010): 1320–28. https://doi.org/10.1016/S0140-6736(10)61274-3.
       Full Text  Link to Item
    • Becker, Richard C., C Michael Gibson, Lisa K. Jennings, and David A. Morrow. “Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.” Am J Cardiol 106, no. 8 (October 15, 2010): S2–3. https://doi.org/10.1016/j.amjcard.2010.08.026.
       Full Text  Link to Item
    • Becker, Richard C. “A clinical cardiology perspective of thrombophilias.” J Thromb Thrombolysis 30, no. 3 (October 2010): 378–89. https://doi.org/10.1007/s11239-010-0511-3.
       Full Text  Link to Item
    • Leonardi, Sergio, Pierluigi Tricoci, and Richard C. Becker. “Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.” Drugs 70, no. 14 (October 1, 2010): 1771–83. https://doi.org/10.2165/11538060-000000000-00000.
       Full Text  Link to Item
    • Shirolkar, Shailesh C., Mona Fiuzat, and Richard C. Becker. “Dronedarone and vitamin K antagonists: a review of drug-drug interactions.” Am Heart J 160, no. 4 (October 2010): 577–82. https://doi.org/10.1016/j.ahj.2010.07.008.
       Full Text  Link to Item
    • Spinler, Sarah A., Kenneth W. Mahaffey, Dianne Gallup, Glenn N. Levine, James J. Ferguson, Sunil V. Rao, Richard Gallo, et al. “Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.” Int J Cardiol 144, no. 1 (September 24, 2010): 36–41. https://doi.org/10.1016/j.ijcard.2009.03.119.
       Full Text  Link to Item
    • Bonello, Laurent, Udaya S. Tantry, Rossella Marcucci, Ruediger Blindt, Dominick J. Angiolillo, Richard Becker, Deepak L. Bhatt, et al. “Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.” J Am Coll Cardiol 56, no. 12 (September 14, 2010): 919–33. https://doi.org/10.1016/j.jacc.2010.04.047.
       Full Text  Link to Item
    • Lou, Junyang, Thomas J. Povsic, Jason D. Allen, Stacie D. Adams, Shelley Myles, Aijing Z. Starr, Thomas L. Ortel, and Richard C. Becker. “The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.” Thromb Res 126, no. 3 (September 2010): e175–79. https://doi.org/10.1016/j.thromres.2009.11.017.
       Full Text  Link to Item
    • Cohen, Mauricio G., Drew A. Purdy, Joseph S. Rossi, Liliana R. Grinfeld, Shelley K. Myles, Laura H. Aberle, Adam B. Greenbaum, et al. “First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.” Circulation 122, no. 6 (August 10, 2010): 614–22. https://doi.org/10.1161/CIRCULATIONAHA.109.927756.
       Full Text  Link to Item
    • Becker, Richard C. “Examining biology and pharmacology-based hypotheses in the PLATO trial.” J Thromb Thrombolysis 30, no. 1 (July 2010): 119–20. https://doi.org/10.1007/s11239-010-0475-3.
       Full Text  Link to Item
    • Woodruff, Becky, Bruce Sullenger, and Richard C. Becker. “Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go?” Curr Cardiol Rep 12, no. 4 (July 2010): 315–20. https://doi.org/10.1007/s11886-010-0117-6.
       Full Text  Link to Item
    • Eisenstein, Eric L., Emily F. Honeycutt, Kevin J. Anstrom, Richard C. Becker, Christopher B. Granger, Sunil V. Rao, Marc E. Jolicoeur, E Magnus Ohman, and E Magnus CATCH Investigators. “Economic assessment of thrombocytopenia: CATCH Registry.” J Med Syst 34, no. 3 (June 2010): 379–86. https://doi.org/10.1007/s10916-008-9250-9.
       Full Text  Link to Item
    • Berger, J. S., and R. C. Becker. “Cardiology,” May 5, 2010, 185–93. https://doi.org/10.1002/9781444306286.ch18.
       Full Text
    • Brummett, Beverly H., Stephen H. Boyle, Thomas L. Ortel, Richard C. Becker, Ilene C. Siegler, and Redford B. Williams. “Associations of depressive symptoms, trait hostility, and gender with C-reactive protein and interleukin-6 response after emotion recall.” Psychosom Med 72, no. 4 (May 2010): 333–39. https://doi.org/10.1097/PSY.0b013e3181d2f104.
       Full Text  Link to Item
    • Lopes, Renato D., David Garcia, Richard C. Becker, Christopher B. Granger, L Kristin Newby, John H. Alexander, E Marc Jolicoeur, et al. “Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.” J Thromb Thrombolysis 29, no. 4 (May 2010): 395–408. https://doi.org/10.1007/s11239-010-0454-8.
       Full Text  Link to Item
    • Rao, Sunil V., Chiara Melloni, Shelley Myles-Dimauro, Samuel Broderick, Andrzej S. Kosinski, Neal S. Kleiman, Vladimír Dzavík, et al. “Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.” Circulation 121, no. 15 (April 20, 2010): 1713–21. https://doi.org/10.1161/CIRCULATIONAHA.109.913277.
       Full Text  Link to Item
    • Dauerman, Harold L., Deepak L. Bhatt, Daniel D. Gretler, Patricia A. French, Susan S. Smyth, and Richard C. Becker. “Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients.” Am Heart J 159, no. 4 (April 2010): 508-517.e1. https://doi.org/10.1016/j.ahj.2010.01.010.
       Full Text  Link to Item
    • Krishnan, Anandi, Renato D. Lopes, John H. Alexander, Richard C. Becker, and Larry B. Goldstein. “Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician.” J Thromb Thrombolysis 29, no. 3 (April 2010): 368–77. https://doi.org/10.1007/s11239-010-0439-7.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., Simon T. Tonev, Sarah A. Spinler, Glenn N. Levine, Richard Gallo, John Ducas, Shaun G. Goodman, et al. “Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.” Int J Cardiol 139, no. 2 (March 4, 2010): 123–33. https://doi.org/10.1016/j.ijcard.2008.10.008.
       Full Text  Link to Item
    • Becker, Richard C., Thomas Povsic, Mauricio G. Cohen, Christopher P. Rusconi, and Bruce Sullenger. “Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics.” Thromb Haemost 103, no. 3 (March 2010): 586–95. https://doi.org/10.1160/TH09-10-0716.
       Full Text  Link to Item
    • Becker, Richard C., and Paul A. Gurbel. “Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies.” Thromb Haemost 103, no. 3 (March 2010): 535–44. https://doi.org/10.1160/TH09-07-0491.
       Full Text  Link to Item
    • Chan, Mark Y., Richard C. Becker, Ling-Ling Sim, Virlynn Tan, Chi-Hang Lee, Adrian F. H. Low, Swee-Guan Teo, Kheng-Siang Ng, Huay-Cheem Tan, and Tiong-Cheng Yeo. “Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function.” Ann Acad Med Singap 39, no. 3 (March 2010): 179–84.
       Link to Item
    • Mackman, Nigel, and Richard C. Becker. “DVT: a new era in anticoagulant therapy.” Arterioscler Thromb Vasc Biol 30, no. 3 (March 2010): 369–71. https://doi.org/10.1161/ATVBAHA.110.203497.
       Full Text  Link to Item
    • Katz, Jason N., Bimal R. Shah, Elizabeth M. Volz, John R. Horton, Linda K. Shaw, L Kristin Newby, Christopher B. Granger, Daniel B. Mark, Robert M. Califf, and Richard C. Becker. “Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes.” Crit Care Med 38, no. 2 (February 2010): 375–81. https://doi.org/10.1097/CCM.0b013e3181cb0a63.
       Full Text  Link to Item
    • Cannon, Christopher P., Robert A. Harrington, Stefan James, Diego Ardissino, Richard C. Becker, Håkan Emanuelsson, Steen Husted, et al. “Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.” Lancet 375, no. 9711 (January 23, 2010): 283–93. https://doi.org/10.1016/S0140-6736(09)62191-7.
       Full Text  Link to Item
    • Becker, R. C. “Reply.” Journal of the American College of Cardiology 55, no. 17 (2010): 1884-. https://doi.org/10.1016/j.jacc.2010.02.012.
       Full Text
    • Chu, S. G., R. C. Becker, P. B. Berger, D. L. Bhatt, J. W. Eikelboom, B. Konkle, E. R. Mohler, M. P. Reilly, and J. S. Berger. “Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis.” J Thromb Haemost 8, no. 1 (January 2010): 148–56. https://doi.org/10.1111/j.1538-7836.2009.03584.x.
       Full Text  Link to Item
    • Povsic, T. J., B. A. Sullenger, S. L. Zelenkofske, C. P. Rusconi, and R. C. Becker. “Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine.” Journal of Cardiovascular Translational Research, 2010, 1–13. https://doi.org/10.1007/s12265-010-9230-6.
       Full Text
    • Roser-Jones, Christopher, and Richard C. Becker. “Apixaban: an emerging oral factor Xa inhibitor.” J Thromb Thrombolysis 29, no. 1 (January 2010): 141–46. https://doi.org/10.1007/s11239-009-0421-4.
       Full Text  Link to Item
    • Kiefer, Todd L., and Richard C. Becker. “Inhibitors of platelet adhesion.” Circulation 120, no. 24 (December 15, 2009): 2488–95. https://doi.org/10.1161/CIRCULATIONAHA.109.886895.
       Full Text  Link to Item
    • Harrington, Robert A., Gregg W. Stone, Steven McNulty, Harvey D. White, A Michael Lincoff, C Michael Gibson, Charles V. Pollack, et al. “Platelet inhibition with cangrelor in patients undergoing PCI.” N Engl J Med 361, no. 24 (December 10, 2009): 2318–29. https://doi.org/10.1056/NEJMoa0908628.
       Full Text  Link to Item
    • Becker, Richard C., James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, et al. “Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.” J Am Coll Cardiol 54, no. 24 (December 8, 2009): 2261–76. https://doi.org/10.1016/j.jacc.2009.09.012.
       Full Text  Link to Item
    • Becker, R. C., and F. Andreotti. “Hemostasis and Thrombosis,” December 1, 2009, 755–72. https://doi.org/10.1016/B978-0-12-369420-1.00063-9.
       Full Text
    • Becker, Richard C., James Scheiman, Harold L. Dauerman, Frederick Spencer, Sunil Rao, Marc Sabatine, David A. Johnson, et al. “Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.” Am J Gastroenterol 104, no. 12 (December 2009): 2903–17. https://doi.org/10.1038/ajg.2009.667.
       Full Text  Link to Item
    • Becker, Richard C., and Mark Y. Chan. “REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.” Curr Opin Mol Ther 11, no. 6 (December 2009): 707–15.
       Link to Item
    • Becker, Richard C. “Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists.” J Thromb Thrombolysis 28, no. 4 (November 2009): 513–14. https://doi.org/10.1007/s11239-009-0385-4.
       Full Text  Link to Item
    • Lopes, Renato D., E Magnus Ohman, Christopher B. Granger, Emily F. Honeycutt, Kevin J. Anstrom, Peter B. Berger, Eric M. Crespo, et al. “Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).” Am J Cardiol 104, no. 9 (November 1, 2009): 1285–91. https://doi.org/10.1016/j.amjcard.2009.06.045.
       Full Text  Link to Item
    • Melloni, Chiara, Ian Fier, James Roach, Andrzej S. Kosinski, Samuel Broderick, Kristina Sigmon, Shelley Myles, Richard C. Becker, Sunil V. Rao, and Sunil V. EMINENCE Investigators. “Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.” Am Heart J 158, no. 5 (November 2009): 726–33. https://doi.org/10.1016/j.ahj.2009.08.020.
       Full Text  Link to Item
    • Sane, David C., Willis Scott Mozingo, and Richard C. Becker. “Cardiac rupture after myocardial infarction: new insights from murine models.” Cardiol Rev 17, no. 6 (November 2009): 293–99. https://doi.org/10.1097/CRD.0b013e3181bf4ab4.
       Full Text  Link to Item
    • Smyth, S. S., R. P. McEver, A. S. Weyrich, C. N. Morrell, M. R. Hoffman, G. M. Arepally, P. A. French, H. L. Dauerman, R. C. Becker, and R. C. 2009 Platelet Colloquium Participants. “Platelet functions beyond hemostasis.” J Thromb Haemost 7, no. 11 (November 2009): 1759–66. https://doi.org/10.1111/j.1538-7836.2009.03586.x.
       Full Text  Link to Item
    • White, M. D., and R. C. Becker. “Fondaparinux in the Cardiac Catheterization Laboratory,” October 30, 2009, 23–30. https://doi.org/10.1002/9781444306347.ch4.
       Full Text
    • Chan, Mark Y., Jeffrey I. Weitz, Yahye Merhi, Robert A. Harrington, and Richard C. Becker. “Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs.” J Thromb Thrombolysis 28, no. 3 (October 2009): 366–80. https://doi.org/10.1007/s11239-009-0375-6.
       Full Text  Link to Item
    • Wallentin, Lars, Richard C. Becker, Andrzej Budaj, Christopher P. Cannon, Håkan Emanuelsson, Claes Held, Jay Horrow, et al. “Ticagrelor versus clopidogrel in patients with acute coronary syndromes.” N Engl J Med 361, no. 11 (September 10, 2009): 1045–57. https://doi.org/10.1056/NEJMoa0904327.
       Full Text  Link to Item
    • Becker, Richard C., Sabah Oney, Kristian C. D. Becker, and Bruce Sullenger. “Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.” Ann N Y Acad Sci 1175 (September 2009): 61–70. https://doi.org/10.1111/j.1749-6632.2009.05017.x.
       Full Text  Link to Item
    • Berger, Jeffrey S., Laine Elliott, Dianne Gallup, Matthew Roe, Christopher B. Granger, Paul W. Armstrong, R John Simes, et al. “Sex differences in mortality following acute coronary syndromes.” Jama 302, no. 8 (August 26, 2009): 874–82. https://doi.org/10.1001/jama.2009.1227.
       Full Text  Link to Item
    • Berger, Jeffrey S., and Richard C. Becker. “A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.” Platelets 20, no. 5 (August 2009): 302–15. https://doi.org/10.1080/09537100903038512.
       Full Text  Link to Item
    • Volovyk, Zoya, Dougald M. Monroe, YiWei Qi, Richard Becker, and Maureane Hoffman. “A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.” J Thromb Thrombolysis 28, no. 2 (August 2009): 132–39. https://doi.org/10.1007/s11239-009-0360-0.
       Full Text  Link to Item
    • Jolicoeur, E Marc, E Magnus Ohman, Emily Honeycutt, Richard C. Becker, Eric M. Crespo, Gustavo B. F. Oliveira, David J. Moliterno, Kevin J. Anstrom, and Christopher B. Granger. “Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin.” Am J Cardiol 104, no. 2 (July 15, 2009): 292–97. https://doi.org/10.1016/j.amjcard.2009.03.034.
       Full Text  Link to Item
    • Becker, R. C., and S. Smyth. “The evolution of platelet-directed pharmacotherapy.” J Thromb Haemost 7 Suppl 1 (July 2009): 266–71. https://doi.org/10.1111/j.1538-7836.2009.03428.x.
       Full Text  Link to Item
    • Lopes, Renato D., Richard C. Becker, David Garcia, Elaine M. Hylek, Christopher B. Granger, Dayse M. Lourenço, Helena B. Nader, et al. “Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil.” J Thromb Thrombolysis 28, no. 1 (July 2009): 106–16. https://doi.org/10.1007/s11239-009-0324-4.
       Full Text  Link to Item
    • Becker, Richard C. “The importance of VTE prevention after orthopaedic surgery.” Lancet 373, no. 9676 (May 16, 2009): 1661–62. https://doi.org/10.1016/S0140-6736(09)60832-1.
       Full Text  Link to Item
    • Gharacholou, S Michael, and Richard C. Becker. “Warfarin in vulnerable older adults with atrial fibrillation.” J Thromb Thrombolysis 27, no. 4 (May 2009): 461–64. https://doi.org/10.1007/s11239-009-0344-0.
       Full Text  Link to Item
    • Chan, M., R. C. Becker, S. H. Shah, and S. R. Levine. “Coagulopathy and Stroke,” April 8, 2009, 152–69. https://doi.org/10.1002/9781444308198.ch12.
       Full Text
    • Becker, Richard C. “Next-generation antithrombin therapies.” J Invasive Cardiol 21, no. 4 (April 2009): 179–85.
       Link to Item
    • Becker, Richard C. “Biomarker science: direction for the scientific community.” J Thromb Thrombolysis 27, no. 3 (April 2009): 355–57. https://doi.org/10.1007/s11239-009-0323-5.
       Full Text  Link to Item
    • Crespo, Eric M., Gustavo B. F. Oliveira, Emily F. Honeycutt, Richard C. Becker, Peter B. Berger, David J. Moliterno, Kevin J. Anstrom, et al. “Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.” Am Heart J 157, no. 4 (April 2009): 651–57. https://doi.org/10.1016/j.ahj.2009.01.005.
       Full Text  Link to Item
    • James, Stefan, Axel Akerblom, Christopher P. Cannon, Håkan Emanuelsson, Steen Husted, Hugo Katus, Allan Skene, et al. “Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.” Am Heart J 157, no. 4 (April 2009): 599–605. https://doi.org/10.1016/j.ahj.2009.01.003.
       Full Text  Link to Item
    • Smyth, Susan S., Donna S. Woulfe, Jeffrey I. Weitz, Christian Gachet, Pamela B. Conley, Shaun G. Goodman, Matthew T. Roe, et al. “G-protein-coupled receptors as signaling targets for antiplatelet therapy.” Arterioscler Thromb Vasc Biol 29, no. 4 (April 2009): 449–57. https://doi.org/10.1161/ATVBAHA.108.176388.
       Full Text  Link to Item
    • Becker, Richard C., David J. Moliterno, Lisa K. Jennings, Karen S. Pieper, Jinglan Pei, Alan Niederman, Khaled M. Ziada, et al. “Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.” Lancet 373, no. 9667 (March 14, 2009): 919–28. https://doi.org/10.1016/S0140-6736(09)60230-0.
       Full Text  Link to Item
    • Becker, Richard C. “Advancing biomarker science in the 21st century.” Circ Cardiovasc Interv 2, no. 1 (February 2009): 4–5. https://doi.org/10.1161/CIRCINTERVENTIONS.109.849067.
       Full Text  Link to Item
    • Gharacholou, S Michael, and Richard C. Becker. “Hemostasis and thrombosis in older adults.” J Thromb Thrombolysis 27, no. 2 (February 2009): 249–51. https://doi.org/10.1007/s11239-009-0308-4.
       Full Text  Link to Item
    • Becker, Richard C. “Thrombogenesis in atrial fibrillation contributing mechanisms and natural history.” J Thromb Thrombolysis 27, no. 1 (January 2009): 119–21. https://doi.org/10.1007/s11239-009-0307-5.
       Full Text  Link to Item
    • Becker, Richard C. “Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists.” Thromb Res 123, no. 3 (2009): 419–28. https://doi.org/10.1016/j.thromres.2008.05.007.
       Full Text  Link to Item
    • Berger, J. S., C. B. Frye, Q. Harshaw, F. H. Edwards, S. R. Steinhubl, and R. C. Becker. “Reply.” Journal of the American College of Cardiology 54, no. 1 (2009): 90–91. https://doi.org/10.1016/j.jacc.2009.03.041.
       Full Text
    • Yavari, Maryam, and Richard C. Becker. “Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass.” J Thromb Thrombolysis 27, no. 1 (January 2009): 95–104. https://doi.org/10.1007/s11239-007-0187-5.
       Full Text  Link to Item
    • Becker, Richard C. “Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history.” J Thromb Thrombolysis 26, no. 3 (December 2008): 262–64. https://doi.org/10.1007/s11239-008-0278-y.
       Full Text  Link to Item
    • Yavari, Maryam, and Richard C. Becker. “Anticoagulant therapy during cardiopulmonary bypass.” J Thromb Thrombolysis 26, no. 3 (December 2008): 218–28. https://doi.org/10.1007/s11239-008-0280-4.
       Full Text  Link to Item
    • Chan, Mark Y., Felicita Andreotti, and Richard C. Becker. “Hypercoagulable states in cardiovascular disease.” Circulation 118, no. 22 (November 25, 2008): 2286–97. https://doi.org/10.1161/CIRCULATIONAHA.108.778837.
       Full Text  Link to Item
    • Berger, Jeffrey S., Carla B. Frye, Qing Harshaw, Fred H. Edwards, Steven R. Steinhubl, and Richard C. Becker. “Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.” J Am Coll Cardiol 52, no. 21 (November 18, 2008): 1693–1701. https://doi.org/10.1016/j.jacc.2008.08.031.
       Full Text  Link to Item
    • Lohrmann, J., and R. C. Becker. “The editorialists reply.” New England Journal of Medicine 359, no. 20 (November 13, 2008): 2176. https://doi.org/10.1056/NEJMc081751.
       Full Text
    • Hylek, Elaine M., and Richard C. Becker. “Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy.” Ann Neurol 64, no. 5 (November 2008): 480–83. https://doi.org/10.1002/ana.21551.
       Full Text  Link to Item
    • Kim, John Hyung-Jun, L Kristin Newby, Robert M. Clare, Linda K. Shaw, Andrew J. Lodge, Peter K. Smith, E Marc Jolicoeur, et al. “Clopidogrel use and bleeding after coronary artery bypass graft surgery.” Am Heart J 156, no. 5 (November 2008): 886–92. https://doi.org/10.1016/j.ahj.2008.06.034.
       Full Text  Link to Item
    • Granger, C. B., E. M. Ohman, and R. C. Becker. “Risk factors for thrombocytopenia in patients treated with prolonged heparin therapy - Reply.” Archives of Internal Medicine 168, no. 19 (October 27, 2008): 2171.
    • Becker, Richard C., and David Sane. “Early career investigator's circle: identifying and nurturing the next generation of scientists and scientific writers.” J Thromb Thrombolysis 26, no. 2 (October 2008): 165. https://doi.org/10.1007/s11239-008-0287-x.
       Full Text  Link to Item
    • Becker, Richard C. “Editor's page: fundamentals in neurocardiology: the brain-platelet-coronary artery interface.” J Thromb Thrombolysis 26, no. 1 (August 2008): 74–77. https://doi.org/10.1007/s11239-008-0255-5.
       Full Text  Link to Item
    • Steinhubl, Steven R., David J. Schneider, Peter B. Berger, and Richard C. Becker. “Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials.” J Thromb Thrombolysis 26, no. 1 (August 2008): 8–13. https://doi.org/10.1007/s11239-007-0160-3.
       Full Text  Link to Item
    • Garcia, David A., Daniel M. Witt, Elaine Hylek, Ann K. Wittkowsky, Edith A. Nutescu, Alan Jacobson, Stephan Moll, et al. “Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum.” Ann Pharmacother 42, no. 7 (July 2008): 979–88. https://doi.org/10.1345/aph.1L098.
       Full Text  Link to Item
    • Lohrmann, Jens, and Richard C. Becker. “New anticoagulants--the path from discovery to clinical practice.” N Engl J Med 358, no. 26 (June 26, 2008): 2827–29. https://doi.org/10.1056/NEJMe0804291.
       Full Text  Link to Item
    • Chan, Mark Y., Mauricio G. Cohen, Christopher K. Dyke, Shelley K. Myles, Laura G. Aberle, Min Lin, James Walder, et al. “Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.” Circulation 117, no. 22 (June 3, 2008): 2865–74. https://doi.org/10.1161/CIRCULATIONAHA.107.745687.
       Full Text  Link to Item
    • Becker, Richard C. “A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy.” J Thromb Thrombolysis 25, no. 3 (June 2008): 300–302. https://doi.org/10.1007/s11239-008-0231-0.
       Full Text  Link to Item
    • Becker, Richard C., Thomas W. Meade, Peter B. Berger, Michael Ezekowitz, Christopher M. O’Connor, David A. Vorchheimer, Gordon H. Guyatt, Daniel B. Mark, and Robert A. Harrington. “The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).” Chest 133, no. 6 Suppl (June 2008): 776S-814S. https://doi.org/10.1378/chest.08-0685.
       Full Text  Link to Item
    • Douketis, James D., Peter B. Berger, Andrew S. Dunn, Amir K. Jaffer, Alex C. Spyropoulos, Richard C. Becker, and Jack Ansell. “The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).” Chest 133, no. 6 Suppl (June 2008): 299S-339S. https://doi.org/10.1378/chest.08-0675.
       Full Text  Link to Item
    • Harrington, Robert A., Richard C. Becker, Christopher P. Cannon, David Gutterman, A Michael Lincoff, Jeffrey J. Popma, Gabriel Steg, Gordon H. Guyatt, and Shaun G. Goodman. “Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).” Chest 133, no. 6 Suppl (June 2008): 670S-707S. https://doi.org/10.1378/chest.08-0691.
       Full Text  Link to Item
    • Kleiman, Neal S., Jane E. Freedman, Paula B. Tracy, Barbara C. Furie, Paul F. Bray, Sunil V. Rao, David R. Phillips, et al. “Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.” Platelets 19, no. 4 (June 2008): 239–51. https://doi.org/10.1080/09537100801947442.
       Full Text  Link to Item
    • Becker, R. C. “Emerging constructs to maintain safety among patients with acute coronary syndromes requiring surgical coronary revascularization.” European Heart Journal, Supplement 10, no. D (May 1, 2008). https://doi.org/10.1093/eurheartj/sun006.
       Full Text
    • Chan, M. Y., C. P. Rusconi, J. H. Alexander, R. M. Tonkens, R. A. Harrington, and R. C. Becker. “A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.” J Thromb Haemost 6, no. 5 (May 2008): 789–96. https://doi.org/10.1111/j.1538-7836.2008.02932.x.
       Full Text  Link to Item
    • Wang, Tracy Y., Anita Y. Chen, Eric D. Peterson, Richard C. Becker, W Brian Gibler, E Magnus Ohman, and Matthew T. Roe. “Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.” Eur Heart J 29, no. 9 (May 2008): 1103–9. https://doi.org/10.1093/eurheartj/ehn126.
       Full Text  Link to Item
    • Becker, Richard C. “Platelet biology for the clinician-scientist: an evolution of understanding.” J Thromb Thrombolysis 25, no. 2 (April 2008): 235–37. https://doi.org/10.1007/s11239-008-0213-2.
       Full Text  Link to Item
    • Chan, Mark Y., Richard C. Becker, Robert A. Harrington, Eric D. Peterson, Paul W. Armstrong, Harvey White, Keith A. A. Fox, E Magnus Ohman, and Matthew T. Roe. “Noninvasive, medical management for non-ST-elevation acute coronary syndromes.” Am Heart J 155, no. 3 (March 2008): 397–407. https://doi.org/10.1016/j.ahj.2007.11.014.
       Full Text  Link to Item
    • Pickard, A Simon, Richard C. Becker, Glen T. Schumock, and Carla B. Frye. “Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting.” Pharmacotherapy 28, no. 3 (March 2008): 376–92. https://doi.org/10.1592/phco.28.3.376.
       Full Text  Link to Item
    • Chan, Mark Y., and Richard C. Becker. “Identification and treatment of arterial thrombophilia.” Curr Treat Options Cardiovasc Med 10, no. 1 (February 2008): 3–11. https://doi.org/10.1007/s11936-008-0001-5.
       Full Text  Link to Item
    • Wang, Tracy Y., Lee A. Robinson, Fang-Shu Ou, Matthew T. Roe, E Magnus Ohman, W Brian Gibler, Sidney C. Smith, Eric D. Peterson, and Richard C. Becker. “Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry.” Am Heart J 155, no. 2 (February 2008): 361–68. https://doi.org/10.1016/j.ahj.2007.09.003.
       Full Text  Link to Item
    • Oliveira, Gustavo B. F., Eric M. Crespo, Richard C. Becker, Emily F. Honeycutt, Charles S. Abrams, Kevin J. Anstrom, Peter B. Berger, et al. “Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.” Arch Intern Med 168, no. 1 (January 14, 2008): 94–102. https://doi.org/10.1001/archinternmed.2007.65.
       Full Text  Link to Item
    • Berger, Jeffrey S., David L. Brown, and Richard C. Becker. “Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.” Am J Med 121, no. 1 (January 2008): 43–49. https://doi.org/10.1016/j.amjmed.2007.10.002.
       Full Text  Link to Item
    • Smyth, Susan S., Dougald M. Monroe, Waldemar E. Wysokinski, Robert D. McBane, Sidney W. Whiteheart, Richard C. Becker, and Steven R. Steinhubl. “Platelet activation and its patient-specific consequences.” Thromb Res 122, no. 4 (2008): 435–41. https://doi.org/10.1016/j.thromres.2007.08.023.
       Full Text  Link to Item
    • Becker, R. C. “Hemostatic aspects of cardiovascular medicine,” December 1, 2007, 339–69. https://doi.org/10.1016/B978-141602401-9.10020-3.
       Full Text
    • Becker, R. C., S. Oney, K. C. D. Becker, C. P. Rusconi, and B. Sullenger. “Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.” Hamostaseologie 27, no. 5 (December 2007): 378–82.
       Link to Item
    • Becker, Richard C. “Thrombotic preparedness in aging: a translatable construct for thrombophilias?” J Thromb Thrombolysis 24, no. 3 (December 2007): 323–25. https://doi.org/10.1007/s11239-007-0094-9.
       Full Text  Link to Item
    • Goldschmid, P. J., N. Lopes, L. E. Crawford, and R. C. Becker. “Atherothrombosis and coronary artery disease,” December 1, 2007, 629–55. https://doi.org/10.1016/B978-012369367-9/50797-7.
       Full Text
    • Gurbel, Paul A., Richard C. Becker, Kenneth G. Mann, Steven R. Steinhubl, and Alan D. Michelson. “Platelet function monitoring in patients with coronary artery disease.” J Am Coll Cardiol 50, no. 19 (November 6, 2007): 1822–34. https://doi.org/10.1016/j.jacc.2007.07.051.
       Full Text  Link to Item
    • Becker, Richard C. “Emerging paradigms, platforms, and unifying themes in biomarker science.” J Am Coll Cardiol 50, no. 18 (October 30, 2007): 1777–80. https://doi.org/10.1016/j.jacc.2007.07.039.
       Full Text  Link to Item
    • Becker, Richard C. “Focus on thrombosis : Applying management guidelines in clinical practice.” J Thromb Thrombolysis 24, no. 2 (October 2007): 183–222. https://doi.org/10.1007/s11239-007-0033-9.
       Full Text  Link to Item
    • Becker, Richard C. “Emergence of factor IXa as a target for pharmacologic inhibition: editors page.” J Thromb Thrombolysis 24, no. 1 (August 2007): 81–83. https://doi.org/10.1007/s11239-007-0030-z.
       Full Text  Link to Item
    • Becker, Richard C. “Platelets from genome to proteome and beyond.” J Thromb Thrombolysis 23, no. 3 (June 2007): 245–48. https://doi.org/10.1007/s11239-006-9008-5.
       Full Text  Link to Item
    • Gurwitz, Jerry H., Terry S. Field, Martha J. Radford, Leslie R. Harrold, Richard Becker, George Reed, Kristin DeBellis, Jason Moldoff, and Nancy Verzier. “The safety of warfarin therapy in the nursing home setting.” The American Journal of Medicine 120, no. 6 (June 2007): 539–44. https://doi.org/10.1016/j.amjmed.2006.07.045.
       Full Text
    • Becker, Richard C. “Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.” J Thromb Thrombolysis 23, no. 2 (April 2007): 159–61. https://doi.org/10.1007/s11239-006-0007-3.
       Full Text  Link to Item
    • Howard, Emily L., Kristian C. D. Becker, Christopher P. Rusconi, and Richard C. Becker. “Factor IXa inhibitors as novel anticoagulants.” Arterioscler Thromb Vasc Biol 27, no. 4 (April 2007): 722–27. https://doi.org/10.1161/01.ATV.0000259363.91070.f1.
       Full Text  Link to Item
    • Katz, Jason N., Aslan T. Turer, and Richard C. Becker. “Cardiology and the critical care crisis: a perspective.” J Am Coll Cardiol 49, no. 12 (March 27, 2007): 1279–82. https://doi.org/10.1016/j.jacc.2006.11.036.
       Full Text  Link to Item
    • Becker, Richard C. “Warfarin-induced vasculopathy.” J Thromb Thrombolysis 23, no. 1 (February 2007): 79–81. https://doi.org/10.1007/s11239-006-9021-8.
       Full Text  Link to Item
    • Welsby, Ian J., Wilbert L. Jones, Gowthami Arepally, Fellery De Lange, Kenji Yoshitani, Barbara Phillips-Bute, Hilary P. Grocott, Richard Becker, and G Burkhard Mackensen. “Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat.” Anesthesiology 106, no. 2 (February 2007): 295–301. https://doi.org/10.1097/00000542-200702000-00018.
       Full Text  Link to Item
    • Becker, Richard C. “Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues.” Thromb Res 119, no. 6 (2007): 761–68. https://doi.org/10.1016/j.thromres.2006.05.014.
       Full Text  Link to Item
    • Oney, S., S. M. Nimjee, J. Layzer, N. Que-Gewirth, D. Ginsburg, R. C. Becker, G. Arepally, and B. A. Sullenger. “Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.” Oligonucleotides 17, no. 3 (2007): 265–74. https://doi.org/10.1089/oli.2007.0089.
       Full Text  Link to Item
    • Dyke, Christopher K., Steven R. Steinhubl, Neal S. Kleiman, Richard O. Cannon, Laura G. Aberle, Min Lin, Shelley K. Myles, et al. “First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.” Circulation 114, no. 23 (December 5, 2006): 2490–97. https://doi.org/10.1161/CIRCULATIONAHA.106.668434.
       Full Text  Link to Item
    • Mahaffey, Kenneth W., and Richard C. Becker. “The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.” Circulation 114, no. 22 (November 28, 2006): 2313–16. https://doi.org/10.1161/CIRCULATIONAHA.106.664169.
       Full Text  Link to Item
    • Becker, Richard C. “Biosignatures in thrombotic disorders.” J Thromb Thrombolysis 22, no. 2 (October 2006): 157–58. https://doi.org/10.1007/s11239-006-9404-x.
       Full Text  Link to Item
    • Becker, Richard C., and Felicita Andreotti. “Preoteomics, metabolomics and progenitor cells in acute coronary syndromes.” J Thromb Thrombolysis 22, no. 1 (August 2006): 85–88. https://doi.org/10.1007/s11239-006-8871-4.
       Full Text  Link to Item
    • Spencer, Frederick A., Cathy Emery, Darleen Lessard, Frederick Anderson, Sri Emani, Jayashri Aragam, Richard C. Becker, and Robert J. Goldberg. “The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.” J Gen Intern Med 21, no. 7 (July 2006): 722–27. https://doi.org/10.1111/j.1525-1497.2006.00458.x.
       Full Text  Link to Item
    • Becker, Richard C. “Modulating atherothrombosis: is there a place for vaccines in global prevention strategies?” J Thromb Thrombolysis 21, no. 3 (June 2006): 285–86. https://doi.org/10.1007/s11239-006-7629-2.
       Full Text  Link to Item
    • Andreotti, Felicita, Alberto Lavorgna, Giulio Coluzzi, Francesca Marzo, Silvia Cecchetti, Elena Conti, and Richard C. Becker. “[Recent advances in atherothrombotic diseases].” Recenti Prog Med 97, no. 4 (April 2006): 183–88.
       Link to Item
    • Becker, Kristian C. D., and Richard C. Becker. “Nucleic acid aptamers as adjuncts to vaccine development.” Curr Opin Mol Ther 8, no. 2 (April 2006): 122–29.
       Link to Item
    • Becker, Richard C. “Preoteomics, metabolomics and circulating endothelial progenitor cells in acute coronary syndromes.” J Thromb Thrombolysis 21, no. 2 (April 2006): 203–6. https://doi.org/10.1007/s11239-006-5969-7.
       Full Text  Link to Item
    • Twomley, Katie M., Sunil V. Rao, and Richard C. Becker. “Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions.” J Thromb Thrombolysis 21, no. 2 (April 2006): 167–74. https://doi.org/10.1007/s11239-006-5206-4.
       Full Text  Link to Item
    • Greenbaum, Adam B., Cindy L. Grines, John A. Bittl, Richard C. Becker, Dean J. Kereiakes, Ian C. Gilchrist, Jane Clegg, et al. “Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.” Am Heart J 151, no. 3 (March 2006): 689.e1-689.e10. https://doi.org/10.1016/j.ahj.2005.11.014.
       Full Text  Link to Item
    • Patel, Manesh R., Trip J. Meine, Lauren Lindblad, Jeffrey Griffin, Christopher B. Granger, Richard C. Becker, Frans Van de Werf, Harvey White, Robert M. Califf, and Robert A. Harrington. “Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.” Am Heart J 151, no. 2 (February 2006): 316–22. https://doi.org/10.1016/j.ahj.2005.04.014.
       Full Text  Link to Item
    • Becker, Richard C., John H. Alexander, Christopher Dyke, Yao Huang, Henock Saint-Jacques, Vic Hasselblad, Robert A. Harrington, Edwin G. Bovill, and Edwin G. XaNADU-1B Investigators. “Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.” Thromb Res 117, no. 4 (2006): 439–46. https://doi.org/10.1016/j.thromres.2005.03.017.
       Full Text  Link to Item
    • Vorchheimer, David A., and Richard Becker. “Platelets in atherothrombosis.” Mayo Clin Proc 81, no. 1 (January 2006): 59–68. https://doi.org/10.4065/81.1.59.
       Full Text  Link to Item
    • Becker, Richard C. “Radiation exposure and coronary atherothrombosis.” J Thromb Thrombolysis 20, no. 3 (December 2005): 191–92. https://doi.org/10.1007/s11239-005-4348-0.
       Full Text  Link to Item
    • Waldo, Albert L., Richard C. Becker, Victor F. Tapson, Kevin J. Colgan, and Kevin J. NABOR Steering Committee. “Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.” J Am Coll Cardiol 46, no. 9 (November 1, 2005): 1729–36. https://doi.org/10.1016/j.jacc.2005.06.077.
       Full Text  Link to Item
    • Becker, Richard C. “Cardiology patient page. Heart attack and stroke prevention in women.” Circulation 112, no. 17 (October 25, 2005): e273–75. https://doi.org/10.1161/CIRCULATIONAHA.105.551341.
       Full Text  Link to Item
    • Harrington, R. A., R. C. Becker, M. Ezekowttz, T. W. Meade, C. C. O’Connor, D. A. Vorchheimer, G. H. Guyatt, et al. “VII. Anticoagulant treatment of coronary disease.” Journal Des Maladies Vasculaires 30, no. SPEC. ISS. 2 (September 1, 2005).
    • Becker, Richard C. “The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.” Am Heart J 150, no. 2 (August 2005): 189–92. https://doi.org/10.1016/j.ahj.2005.04.006.
       Full Text  Link to Item
    • Becker, Richard C. “Cell-based models of coagulation: a paradigm in evolution.” J Thromb Thrombolysis 20, no. 1 (August 2005): 65–68. https://doi.org/10.1007/s11239-005-3118-3.
       Full Text  Link to Item
    • Tapson, Victor F., Thomas M. Hyers, Albert L. Waldo, David J. Ballard, Richard C. Becker, Joseph A. Caprini, Roger Khetan, et al. “Antithrombotic therapy practices in US hospitals in an era of practice guidelines.” Arch Intern Med 165, no. 13 (July 11, 2005): 1458–64. https://doi.org/10.1001/archinte.165.13.1458.
       Full Text  Link to Item
    • Armani, Annemarie, and Richard C. Becker. “The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II.” Am Heart J 149, no. 6 (June 2005): 977–83. https://doi.org/10.1016/j.ahj.2004.12.032.
       Full Text  Link to Item
    • Armani, Annemarie, and Richard C. Becker. “The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I.” Am Heart J 149, no. 6 (June 2005): 971–76. https://doi.org/10.1016/j.ahj.2004.12.031.
       Full Text  Link to Item
    • Becker, Richard C. “Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm.” J Thromb Thrombolysis 19, no. 3 (June 2005): 215–17. https://doi.org/10.1007/s11239-005-1858-8.
       Full Text  Link to Item
    • Becker, Richard C., Christopher Rusconi, and Bruce Sullenger. “Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application.” Thromb Haemost 93, no. 6 (June 2005): 1014–20. https://doi.org/10.1160/TH04-12-0790.
       Full Text  Link to Item
    • Andreotti, Felicita, and Richard C. Becker. “Atherothrombotic disorders: new insights from hematology.” Circulation 111, no. 14 (April 12, 2005): 1855–63. https://doi.org/10.1161/01.CIR.0000160361.73423.23.
       Full Text  Link to Item
    • Becker, Richard C. “The importance of factor Xa regulatory pathways in vascular thromboresistance: focus on protein Z.” J Thromb Thrombolysis 19, no. 2 (April 2005): 135–37. https://doi.org/10.1007/s11239-005-2473-4.
       Full Text  Link to Item
    • Alexander, J. H., H. Yang, R. C. Becker, K. Kodama, S. Goodman, C. K. Dyke, N. S. Kleiman, et al. “First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.” J Thromb Haemost 3, no. 3 (March 2005): 439–47. https://doi.org/10.1111/j.1538-7836.2004.01081.x.
       Full Text  Link to Item
    • Becker, Richard C. “The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort.” Eur Heart J 26, no. 5 (March 2005): 421–22. https://doi.org/10.1093/eurheartj/ehi125.
       Full Text  Link to Item
    • Becker, Richard C. “Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.” J Thromb Thrombolysis 19, no. 1 (February 2005): 71–75. https://doi.org/10.1007/s11239-005-0943-3.
       Full Text  Link to Item
    • Ohman, E Magnus, Christopher B. Granger, Lawrence Rice, Charles S. Abrams, Richard C. Becker, Peter B. Berger, Neal S. Kleiman, et al. “Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee.” J Thromb Thrombolysis 19, no. 1 (February 2005): 11–19. https://doi.org/10.1007/s11239-005-0850-7.
       Full Text  Link to Item
    • Becker, R. C. “Keynote address: COX-2 inhibitors.” Texas Heart Institute Journal 32, no. 3 (January 1, 2005): 380–83.
    • Becker, Richard C. “COX-2 inhibitors.” Tex Heart Inst J 32, no. 3 (2005): 380–83.
       Link to Item
    • Becker, Richard C. “Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician.” Am Heart J 149, no. 1 Suppl (January 2005): S2–8. https://doi.org/10.1016/j.ahj.2004.10.017.
       Full Text  Link to Item
    • Becker, Richard C. “Novel constructs for thrombin inhibition.” Am Heart J 149, no. 1 Suppl (January 2005): S61–72. https://doi.org/10.1016/j.ahj.2004.10.024.
       Full Text  Link to Item
    • Becker, Richard C. “Thrombin: science and application in clinical practice.” Am Heart J 149, no. 1 Suppl (January 2005): S1. https://doi.org/10.1016/j.ahj.2004.10.016.
       Full Text  Link to Item
    • Becker, Richard C., John Alexander, Christopher K. Dyke, and Robert A. Harrington. “Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.” Thromb Haemost 92, no. 6 (December 2004): 1182–93. https://doi.org/10.1160/TH04-05-0289.
       Full Text  Link to Item
    • Becker, Richard C., John Alexander, You Fu Li, Edwin Bovill, Frederick A. Spencer, Thomas L. Robertson, Satoshi Kunitada, Christopher K. Dyke, and Robert A. Harrington. “Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.” Thromb Haemost 92, no. 6 (December 2004): 1229–31.
       Link to Item
    • Becker, Richard C., John H. Alexander, Youfu Li, Thomas Robertson, Satoshi Kunitada, Frederick A. Spencer, Hongqiu Yang, and Robert A. Harrington. “Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.” J Thromb Thrombolysis 18, no. 3 (December 2004): 193–97. https://doi.org/10.1007/s11239-005-0345-6.
       Full Text  Link to Item
    • Spencer, Frederick A., Gregg C. Fonarow, Paul D. Frederick, R Scott Wright, Nathan Every, Robert J. Goldberg, Joel M. Gore, et al. “Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.” Arch Intern Med 164, no. 19 (October 25, 2004): 2162–68. https://doi.org/10.1001/archinte.164.19.2162.
       Full Text  Link to Item
    • Becker, Richard C. “Factor Xa-protease activated receptor interface: a paradigm for combination pharmacotherapy.” J Thromb Thrombolysis 18, no. 2 (October 2004): 153–55. https://doi.org/10.1007/s11239-004-0212-x.
       Full Text  Link to Item
    • Harrington, Robert A., Richard C. Becker, Michael Ezekowitz, Thomas W. Meade, Christopher M. O’Connor, David A. Vorchheimer, and Gordon H. Guyatt. “Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.” Chest 126, no. 3 Suppl (September 2004): 513S-548S. https://doi.org/10.1378/chest.126.3_suppl.513S.
       Full Text  Link to Item
    • Becker, Richard C. “Optimizing heparin compounds: a working construct for future antithrombotic drug development.” J Thromb Thrombolysis 18, no. 1 (August 2004): 55–58. https://doi.org/10.1007/s11239-004-0176-x.
       Full Text  Link to Item
    • Li, Youfu, Kristian C. D. Becker, David Slatkin, Frederick Spencer, and Richard C. Becker. “The effect of temperature variation in vitro on platelet-leukocyte interactions and individual prothrombotic potential.” J Thromb Thrombolysis 18, no. 1 (August 2004): 19–23. https://doi.org/10.1007/s11239-004-0169-9.
       Full Text  Link to Item
    • Petersen, John L., Kenneth W. Mahaffey, Richard C. Becker, Shaun G. Goodman, Neal S. Kleiman, A. J. Marian, Gregg W. Stone, et al. “Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.” Am Heart J 148, no. 2 (August 2004): 269–76. https://doi.org/10.1016/j.ahj.2004.03.022.
       Full Text  Link to Item
    • Becker, Richard C. “Protein-binding oligonucleotides: the next frontier in antithrombotic therapy.” J Thromb Thrombolysis 17, no. 2 (April 2004): 157–59. https://doi.org/10.1023/B:THRO.0000037673.15166.38.
       Full Text  Link to Item
    • Becker, Richard C. “Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy.” Clin Cardiol 27, no. 3 (March 2004): 119–20. https://doi.org/10.1002/clc.4960270303.
       Full Text  Link to Item
    • Alexander, J. H., C. K. Dyke, H. Yang, R. C. Becker, V. Hasselblad, L. A. Zillman, N. S. Kleiman, et al. “Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.” J Thromb Haemost 2, no. 2 (February 2004): 234–41. https://doi.org/10.1111/j.1538-7933.2004.00594.x.
       Full Text  Link to Item
    • Ferguson, J. J., R. M. Califf, E. M. Antman, M. Cohen, C. L. Grines, S. Goodman, D. J. Kereiakes, et al. “Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.” Jama : The Journal of the American Medical Association 292, no. 1 (2004): 45–54.
    • Spencer, F. A., and R. C. Becker. “When guidelines collide.” American Heart Journal 147, no. 3 (2004): 395–97. https://doi.org/10.1016/j.ahj.2003.09.017.
       Full Text
    • Kim, Robert J., and Richard C. Becker. “Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.” Am Heart J 146, no. 6 (December 2003): 948–57. https://doi.org/10.1016/S0002-8703(03)00519-2.
       Full Text  Link to Item
    • Becker, Richard C. “Factor Xa-A pleuripotential protease.” J Thromb Thrombolysis 15, no. 1 (February 2003): 5–9. https://doi.org/10.1023/a:1026106915960.
       Full Text  Link to Item
    • Elsayed, Essam, and Richard C. Becker. “The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.” J Thromb Thrombolysis 15, no. 1 (February 2003): 11–18. https://doi.org/10.1023/a:1026184100030.
       Full Text  Link to Item
    • Li, You fu, Frederick A. Spencer, and Richard C. Becker. “Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.” J Thromb Thrombolysis 15, no. 1 (February 2003): 19–23. https://doi.org/10.1023/a:1026136216869.
       Full Text  Link to Item
    • Becker, R. C. “Complicated Myocardial Infarction.” Critical Pathways in Cardiology 2, no. 2 (2003): 125–52. https://doi.org/10.1097/01.hpc.0000084011.53699.d0.
       Full Text
    • Becker, R., S. Butenas, M. C. Jr, F. Jaffer, N. S. Kleiman, J. D. Marmur, D. J. Schneider, B. D. Spiess, S. R. Steinhubl, and J. I. Weitz. “Bivalirudin, thrombin and platelets: Clinical implications and future directions.” Journal of Invasive Cardiology 15, no. 8 SUPPL. (2003): 1–15.
    • Becker, R., S. Butenas, M. Carr, F. Jaffer, N. S. Kleiman, J. D. Marmur, D. J. Schneider, B. D. Spiess, S. R. Steinhubl, and J. I. Weitz. “Bivalirudin, thrombin and platelets: clinical implications and future directions.” The Journal of Invasive Cardiology Suppl (2003): 2–15.
    • Bruno, R., P. Baille, S. Retout, N. Vivier, C. Veyrat-Follet, G. J. Sanderink, R. Becker, and E. M. Antman. “Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.” British Journal of Clinical Pharmacology 56, no. 4 (2003): 407–14. https://doi.org/10.1046/j.1365-2125.2003.01904.x.
       Full Text
    • French, John K., Neil S. Van de Water, Timothy M. Sutton, Mayanna Lund, WanZhen Gao, Joanne McDowell, Yiwen Liu-Stratton, et al. “Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction.” Am Heart J 145, no. 1 (January 2003): 118–24. https://doi.org/10.1067/mhj.2003.29.
       Full Text  Link to Item
    • Spencer, F. A., and R. C. Becker. “Circadian variations in acute myocardial infarction: Patients or health care delivery?” Journal of the American College of Cardiology 41, no. 12 (2003): 2143–46. https://doi.org/10.1016/S0735-1097(03)00462-5.
       Full Text
    • Freedman, Jane E., Richard C. Becker, Jesse E. Adams, Steven Borzak, Robert L. Jesse, L Kristin Newby, Patrick O’Gara, et al. “Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke.” Circulation 106, no. 20 (November 12, 2002): 2623–29. https://doi.org/10.1161/01.cir.0000037748.19282.7d.
       Full Text  Link to Item
    • Dyke, Christopher K., Richard C. Becker, Neal S. Kleiman, Judith S. Hochman, Edwin G. Bovill, A Michael Lincoff, Gary Gerstenblith, et al. “First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.” Circulation 105, no. 20 (May 21, 2002): 2385–91. https://doi.org/10.1161/01.cir.0000016351.12759.52.
       Full Text  Link to Item
    • Ali, O. A., N. Okike, R. G. Hogan, and R. C. Becker. “Intramural hematoma of the thoracic aorta in a woman with neurofibromatosis.” Annals of Thoracic Surgery 73, no. 3 (2002): 958–60. https://doi.org/10.1016/S0003-4975(01)03018-1.
       Full Text
    • Becker, R. C. “Antithrombotic therapy after myocardial infarction.” New England Journal of Medicine 347, no. 13 (2002): 1019–22. https://doi.org/10.1056/NEJMe020097.
       Full Text
    • Becker, R. C. “Choice of agents to limit the coagulation cascade in acute coronary syndromes.” Current Cardiology Reports 4, no. 4 (2002): 272–77. https://doi.org/10.1007/s11886-002-0062-0.
       Full Text
    • Becker, R. C., F. A. Spencer, M. Gibson, J. E. Rush, G. Sanderink, S. A. Murphy, S. P. Ball, and E. M. Antman. “Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.” American Heart Journal 143, no. 5 (2002): 753–59. https://doi.org/10.1067/mhj.2002.120774.
       Full Text
    • Bonow, R. O., W. E. Mitch, R. W. Nesto, P. T. O’Gara, R. C. Becker, L. T. Clark, S. Hunt, I. Jialal, S. E. Lipshultz, and E. Loh. “Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal complications.” Circulation 105, no. 18 (2002): e159–64.
    • Harrold, L. R., J. H. Gurwitz, J. P. Tate, R. Becker, T. Stuart, A. Elwell, and M. Radford. “Physician attitudes concerning anticoagulation services in the long-term care setting.” Journal of Thrombosis and Thrombolysis 14, no. 1 (2002): 59–64. https://doi.org/10.1023/A:1022018422237.
       Full Text
    • Li, Y. F., F. A. Spencer, and R. C. Becker. “Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.” American Heart Journal 143, no. 4 (2002): 725–32. https://doi.org/10.1067/mhj.2002.120299.
       Full Text
    • Li, Y. F., M. Rodriguez, F. A. Spencer, and R. C. Becker. “Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: A model for assessing intrinsic thromboresistance.” Journal of Thrombosis and Thrombolysis 14, no. 2 (2002): 123–29. https://doi.org/10.1023/A:1023280811804.
       Full Text
    • Andrew, M., J. L. Ansell, D. M. Becker, R. C. Becker, and D. A. Triplett. “Point-of-care prothrombin time measurement for professional and patient self-testing use: A multicenter clinical experience.” American Journal of Clinical Pathology 115, no. 2 (2001): 288–96. https://doi.org/10.1309/KM0J-G5V9-KCAG-CLEE.
       Full Text
    • Andrews, M., J. L. Ansell, D. M. Becker, R. C. Becker, and D. A. Triplett. “Prothrombin measurement using a patient self-testing system.” American Journal of Clinical Pathology 115, no. 2 (2001): 280–87.
    • Becker, R. C. “Anticoagulation and the heart.” Journal of Thrombosis and Thrombolysis 12, no. 1 (2001): 41–52. https://doi.org/10.1023/A:1012786410881.
       Full Text
    • Becker, R. C. “Markers of platelet activation and thrombin generation.” Cardiovascular Toxicology 1, no. 2 (2001): 141–45.
    • Becker, R. C., M. Burns, N. Every, C. Maynard, P. Frederick, F. A. Spencer, J. M. Gore, and C. Lambrew. “Early clinical outcomes and routine management of patients with non-ST-segment elevation myocardial infarction: A nationwide perspective.” Archives of Internal Medicine 161, no. 4 (2001): 601–7.
    • Becker, R. C., P. Eisenberg, and A. G. G. Turpie. “Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: Fundamental principles and the contribution of platelets and thrombin.” American Heart Journal 141, no. 6 (2001): 1025–37. https://doi.org/10.1067/mhj.2001.115492.
       Full Text
    • Husted, S., R. Becker, and A. Kher. “A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery disease.” Clinical Cardiology 24, no. 7 (2001): 492–99.
    • Kimmelstiel, C., R. Phang, A. Rehman, W. Rand, R. Miele, J. Rhofiry, D. A. MacIsaac, W. Gouveia, D. Denier, and R. C. Becker. “Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.” Journal of Thrombosis and Thrombolysis 11, no. 3 (2001): 203–9. https://doi.org/10.1023/A:1011904718960.
       Full Text
    • Li, Y. F., F. A. Spencer, and R. C. Becker. “Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (αIIb/β₃) receptor-directed platelet inhibition.” American Heart Journal 142, no. 2 (2001): 204–10. https://doi.org/10.1067/mhj.2001.116962.
       Full Text
    • McCormick, D., J. H. Gurwitz, R. J. Goldberg, R. Becker, J. P. Tate, A. Elwell, and M. J. Radford. “Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.” Archives of Internal Medicine 161, no. 20 (2001): 2458–63.
    • Spencer, F. A., R. J. Goldberg, P. D. Frederick, J. Malmgren, R. C. Becker, and J. M. Gore. “Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]).” American Journal of Cardiology 88, no. 2 (2001): 107–11. https://doi.org/10.1016/S0002-9149(01)01602-2.
       Full Text
    • Becker, R. C. “Heparins in management of acute coronary syndromes without ST-segment elevation.” Lancet 355, no. 9219 (2000): 1926–28.
    • Becker, R. C. “The scientific basis for combined platelet and thrombin-directed pharmacotherapy in Acute Coronary Syndromes.” Journal of Invasive Cardiology 12, no. SUPPL. E (2000): E19–24.
    • Becker, R. C. “Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting.” Journal of Thrombosis and Thrombolysis 10, no. SUPPL. 1 (2000): S59–68.
    • Becker, R. C. “Heparin-induced thrombocytopenia: Supplement to the journal of thrombosis and thrombolysis.” Journal of Thrombosis and Thrombolysis 10, no. SUPPL. 1 (2000).
    • Becker, R. C. “Platelet surface physiology and its importance in pharmacotherapy design and development: The adenosine diphosphate receptor antagonists.” Journal of Thrombosis and Thrombolysis 10, no. 1 (2000): 35–53.
    • Becker, R. C. “Key references: Cardiac rupture.” Journal of Thrombosis and Thrombolysis 9, no. 1 (2000): 77–80.
    • Becker, R. C. “Key references: anticoagulants and coagulation monitoring.” Journal of Thrombosis and Thrombolysis 9, no. 1 (2000): 69–76.
    • Becker, R. C., G. J. Merli, and R. L. Talbert. “Recent strides in antithrombotic therapy.” Patient Care 34, no. 15 (2000): 20–42.
    • Becker, R. C., M. Burns, J. M. Gore, C. Lambrew, W. French, and W. J. Rogers. “Early and pre-discharge aspirin administration among patients with acute myocardial infarction: Current clinical practice and trends in the United States.” Journal of Thrombosis and Thrombolysis 9, no. 3 (2000): 207–15.
    • Becker, R. C., and O. Ali. “Low molecular weight heparin in acute coronary syndromes - The emergence of dalteparin.” Today’S Therapeutic Trends 18, no. 2 (2000): 149–64.
    • Every, N. R., J. Hochman, R. Becker, S. Kopecky, and C. P. Cannon. “Critical pathways: A review.” Circulation 101, no. 4 (2000): 461–65.
    • Li, Y., F. A. Spencer, S. Ball, and R. C. Becker. “Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes.” Journal of Thrombosis and Thrombolysis 10, no. 1 (2000): 69–76.
    • Singer, I. O., D. Murdoch, R. C. Tait, and R. C. Becker. “Low-molecular-weight heparin as optimal solution to therapeutic heparinization [3] (multiple letters).” American Heart Journal 139, no. 3 (2000): 558–61.
    • Spencer, F. A., S. P. Ball, Q. Zhang, L. Liu, S. Benoit, and R. C. Becker. “Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.” Journal of Thrombosis and Thrombolysis 9, no. 3 (2000): 223–28.
    • Spencer, F. A., and R. C. Becker. “Novel inhibitors of factor X for use in cardiovascular diseases.” Current Cardiology Reports 2, no. 5 (2000): 395–404. https://doi.org/10.1007/s11886-000-0052-z.
       Full Text
    • Bartunek, J., M. Vanderheyden, B. D. Bruyne, R. C. Becker, and G. Aurigemma. “Dynamic left ventricular outflow tract obstruction as a potential mechanism of myocardial rupture after acute myocardial infarction [4] (multiple letters).” Journal of the American College of Cardiology 34, no. 7 (1999): 2150–51.
    • Becker, R. C. “Thrombosis and the role of the platelet.” American Journal of Cardiology 83, no. 9 A (1999): 3E-6E.
    • Becker, R. C. “New thrombolytic, anticoagulants, and platelet antagonists: The future of clinical practice.” Journal of Thrombosis and Thrombolysis 7, no. 2 (1999): 195–220. https://doi.org/10.1023/A:1008845822884.
       Full Text
    • Becker, R. C., F. A. Spencer, Y. Li, S. P. Ball, Y. Ma, T. Hurley, and J. Hebert. “Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential.” Journal of the American College of Cardiology 34, no. 4 (1999): 1020–27. https://doi.org/10.1016/S0735-1097(99)00322-8.
       Full Text
    • Becker, R. C., J. S. Hochman, C. P. Cannon, F. A. Spencer, S. P. Ball, M. J. Rizzo, and E. M. Antman. “Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study.” Journal of the American College of Cardiology 33, no. 2 (1999): 479–87. https://doi.org/10.1016/S0735-1097(98)00582-8.
       Full Text
    • Becker, R. C., S. P. Ball, P. Eisenberg, S. Borzak, A. C. Held, F. Spencer, S. J. Voyce, et al. “A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease.” American Heart Journal 137, no. 1 (1999): 59–71. https://doi.org/10.1016/S0002-8703(99)70460-6.
       Full Text
    • Dickson, E. W., C. P. Reinhardt, F. P. Renzi, R. C. Becker, W. A. Porcaro, and S. O. Heard. “Ischemic preconditioning may be transferable via whole blood transfusion: Preliminary evidence.” Journal of Thrombosis and Thrombolysis 8, no. 2 (1999): 123–29. https://doi.org/10.1023/A:1008911101951.
       Full Text
    • Spencer, F. A., and R. C. Becker. “Diagnosis and management of inherited and acquired thrombophilias.” Journal of Thrombosis and Thrombolysis 7, no. 2 (1999): 91–104. https://doi.org/10.1023/A:1008817116524.
       Full Text
    • “Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.” J Am Coll Cardiol 32, no. 7 (December 1998): 2003–10. https://doi.org/10.1016/s0735-1097(98)00474-4.
       Full Text  Link to Item
    • Zabel, K. M., C. B. Granger, R. C. Becker, E. G. Bovill, J. Hirsh, P. E. Aylward, E. J. Topol, and R. M. Califf. “Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.” Am Heart J 136, no. 5 (November 1998): 868–76. https://doi.org/10.1016/s0002-8703(98)70133-4.
       Full Text  Link to Item
    • Granger, C. B., R. Becker, R. P. Tracy, R. M. Califf, E. J. Topol, K. S. Pieper, A. M. Ross, S. Roth, C. Lambrew, and E. G. Bovill. “Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.” J Am Coll Cardiol 31, no. 3 (March 1, 1998): 497–505. https://doi.org/10.1016/s0735-1097(97)00539-1.
       Full Text  Link to Item
    • Becker, R. C. “A clinician's view of thrombotic disorders of the cardiovascular system.” Archives of Pathology & Laboratory Medicine 122, no. 9 (1998): 815–16.
    • Becker, R. C., E. G. Bovill, M. J. Seghatchian, and M. M. Samama. “Pathobiology of thrombin in acute coronary syndromes.” American Heart Journal 136, no. 4 II SUPPL. (1998): S19–31. https://doi.org/10.1053/hj.1998.v136.93435.
       Full Text
    • Becker, R. C., M. Burns, J. M. Gore, F. A. Spencer, S. P. Ball, W. French, C. Lambrew, L. Bowlby, J. Hilbe, and W. J. Rogers. “Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: A nationwide perspective of current clinical practice.” American Heart Journal 135, no. 5 I (1998): 786–96. https://doi.org/10.1016/S0002-8703(98)70036-5.
       Full Text
    • Becker, R. C., and F. A. Spencer. “Thrombin: Structure, biochemistry, measurement, and status in clinical medicine.” Journal of Thrombosis and Thrombolysis 5, no. 3 (1998): 215–29. https://doi.org/10.1023/A:1008843925851.
       Full Text
    • Becker, R. C., and F. Spencer. “Guidelines for the management of patients with acute myocardial infarction.” Journal of Thrombosis and Thrombolysis 5, no. 1 (1998): 73–81. https://doi.org/10.1023/A:1008809723703.
       Full Text
    • Borzak, S., C. P. Cannon, P. L. Kraft, L. Douthat, R. C. Becker, S. T. Palmeri, T. Henry, et al. “Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina.” American Journal of Cardiology 81, no. 6 (1998): 678–81. https://doi.org/10.1016/S0002-9149(97)01006-0.
       Full Text
    • Bovill, E. G., K. G. Mann, D. Phillips, G. Vlasuk, and R. C. Becker. “College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: Future directions.” Archives of Pathology and Laboratory Medicine 122, no. 9 (1998): 808–16.
    • Campbell, R. W. F., L. Wallentin, F. W. A. Verbeugt, A. G. G. Turpie, A. Maseri, W. Klein, J. G. F. Cleland, et al. “Management strategies for a better outcome in unstable coronary artery disease.” Clinical Cardiology 21, no. 5 (1998): 314–22.
    • Furman, M. I., L. Liu, S. E. Benoit, R. C. Becker, M. R. Barnard, and A. D. Michelson. “The cleaved peptide of the thrombin receptor is a strong platelet agonist.” Proceedings of the National Academy of Sciences of the United States of America 95, no. 6 (1998): 3082–87. https://doi.org/10.1073/pnas.95.6.3082.
       Full Text
    • Furman, M. I., S. E. Benoit, M. R. Barnard, C. R. Valeri, M. L. Borbone, R. C. Becker, H. B. Hechtman, and A. D. Michelson. “Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.” Journal of the American College of Cardiology 31, no. 2 (1998): 352–58. https://doi.org/10.1016/S0735-1097(97)00510-X.
       Full Text
    • Spencer, F. A., R. J. Goldberg, R. C. Becker, and J. M. Gore. “Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction.” Journal of the American College of Cardiology 31, no. 6 (1998): 1226–33. https://doi.org/10.1016/S0735-1097(98)00098-9.
       Full Text
    • Hennekens, C. “The need for wider utilization of thrombolytic therapy.” Clin Cardiol 20, no. 11 Suppl 3 (November 1997): III26–31. https://doi.org/10.1002/clc.4960201408.
       Full Text  Link to Item
    • Newby, K. “Clinical outcomes according to time to treatment.” Clin Cardiol 20, no. 11 Suppl 3 (November 1997): III11–15. https://doi.org/10.1002/clc.4960201405.
       Full Text  Link to Item
    • Spencer, F. A., R. C. Becker, and J. Alexander. “The prothrombinase complex: Assembly and function.” Journal of Thrombosis and Thrombolysis 4, no. 3–4 (September 12, 1997): 357–64. https://doi.org/10.1023/A:1008897300003.
       Full Text
    • Becker, R. C. “Incidence of stroke may be on the rise.” Stroke; a Journal of Cerebral Circulation 28, no. 9 (1997): 1657–59.
    • Becker, R. C. “Dynamics of coronary thrombolysis and reocclusion.” Clinical Cardiology 20, no. 11 SUPPL. (1997): III2–5.
    • Becker, R. C. “Editorial.” Stroke 28, no. 9 (1997): 1657-.
    • Becker, R. C., and F. Spencer. “Adjunctive pharmacologic treatment: Focus on the development of low molecular weight heparins.” Journal of Thrombosis and Thrombolysis 4, no. 2 (1997): 197–206. https://doi.org/10.1023/A:1008870228789.
       Full Text
    • Becker, R. C., and J. Ansell. “The need for long-term anticoagulants in venous thromboembolism: How long?” Clinical and Applied Thrombosis/Hemostasis 3, no. 1 SUPPL. (1997): S8–15. https://doi.org/10.1177/107602969700300103.
       Full Text
    • Bracken, J., R. C. Becker, A. Zweifler, and J. M. Rawles. “Reducing door-to-needle time: Treatment delay versus presentation delay.” Clinical Cardiology 20, no. 11 SUPPL. (1997): III21–25.
    • Hochman, J. S., C. H. McCabe, P. H. Stone, R. C. Becker, C. P. Cannon, T. Defeo-Fraulini, B. Thompson, R. Steingart, G. Knatterud, and E. Braunwald. “Outcome and profile of women and men presenting with acute coronary syndromes: A report from TIMI IIIB.” Journal of the American College of Cardiology 30, no. 1 (1997): 141–48. https://doi.org/10.1016/S0735-1097(97)00107-1.
       Full Text
    • Moore, W. E., C. Hennekens, R. C. Becker, and A. Zweifler. “Prehospital strategies to expedite myocardial salvage.” Clinical Cardiology 20, no. 11 SUPPL. (1997): III16–20.
    • Pollak, H., and R. C. Becker. “Thrombolysis, the risk of rupture and other risks [1].” Journal of the American College of Cardiology 29, no. 1 (1997): 221–22.
    • Sharma, M., M. I. Furman, F. A. Spencer, M. Burns, S. P. Ball, and R. C. Becker. “Current and practical management of acute myocardial infarction.” Journal of Thrombosis and Thrombolysis 4, no. 3–4 (1997): 375–96. https://doi.org/10.1023/A:1008801500912.
       Full Text
    • Sharma, M., M. I. Furman, F. A. Spencer, M. Burns, S. P. Ball, and R. C. Becker. “Thrombolytic therapy in acute myocardial infarction: Management algorithms.” Journal of Thrombosis and Thrombolysis 4, no. 3–4 (1997): 397–413. https://doi.org/10.1023/A:1008853517750.
       Full Text
    • Becker, R. C. “Early cardiac rupture - A possible complication of thrombolytic and antithrombotic therapy.” Cardiology Review 13, no. 11 (1996): 8–17.
    • Becker, R. C. “Toward achieving optimal patient care in 1996: An introduction to the National Heart Attack Alert Program.” Journal of Thrombosis and Thrombolysis 3, no. 3 (1996).
    • Becker, R. C., C. P. Cannon, E. G. Bovill, R. P. Tracy, B. Thompson, G. L. Knatterud, A. Randall, and E. Braunwald. “Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial).” American Journal of Cardiology 78, no. 2 (1996): 142–47. https://doi.org/10.1016/S0002-9149(96)00247-0.
       Full Text
    • Becker, R. C., C. P. Cannon, R. P. Tracy, B. Thompson, E. G. Bovill, P. Desvigne-Nickens, A. M. Y. Randall, G. Knatternud, and E. Braunwald. “Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction.” American Heart Journal 131, no. 3 (1996): 421–33. https://doi.org/10.1016/S0002-8703(96)90519-0.
       Full Text
    • Becker, R. C., J. M. Gore, C. Lambrew, W. D. Weaver, R. M. Rubison, W. J. French, A. J. Tiefenbrunn, L. J. Bowlby, and W. J. Rogers. “A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction.” Journal of the American College of Cardiology 27, no. 6 (1996): 1321–26. https://doi.org/10.1016/0735-1097(96)00008-3.
       Full Text
    • Becker, R. C., T. Hurley, Y. Ma, and J. R. Hebert. “Editorial: Evolution of direct thrombin antagonists: Acknowledging potential limitations.” Journal of Thrombosis and Thrombolysis 3, no. 1 (1996): 23–27.
    • Foley, J. A., and R. C. Becker. “Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment?” Cardiovascular Drugs and Therapy 10, no. 4 (1996): 403–7. https://doi.org/10.1007/BF00051103.
       Full Text
    • Furman, M. I., R. C. Becker, J. Yarzebski, J. Savegeau, J. M. Gore, and R. J. Goldberg. “Effect of elevated leukocyte count on in-hospitalmortality following acute myocardial infarction.” American Journal of Cardiology 78, no. 8 (1996): 945–48.
    • Scharfstein, J. S., D. R. Abendschein, P. R. Eisenberg, D. George, C. P. Cannon, R. C. Becker, B. Sobel, L. A. Cupples, E. Braunwald, and J. Loscalzo. “Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction.” American Journal of Cardiology 78, no. 5 (1996): 503–10.
    • Spencer, F., and R. C. Becker. “Current approach to antithrombotic therapy: An abbreviated reference for practicing clinicians.” Journal of Thrombosis and Thrombolysis 3, no. 4 (1996): 307–25.
    • Spencer, F., and R. C. Becker. “Anticoagulation in congestive cardiomyopathy: Steps toward defining the great unknown.” Journal of Thrombosis and Thrombolysis 3, no. 3 (1996): 171–79.
    • Terlato, R. J., S. E. Kopec, C. K. Aaron, L. I. Laifer, and R. C. Becker. “Massive overdose of Cardizem CD.” Journal of Intensive Care Medicine 11, no. 2 (1996): 108–13.
    • Becker, R. C. “Future directions.” Journal of Thrombosis and Thrombolysis 1, no. 3 (1995). https://doi.org/10.1007/BF01060730.
       Full Text
    • Becker, R. C. “Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis.” Journal of Thrombosis and Thrombolysis 1, no. 2 (1995): 133–44. https://doi.org/10.1007/BF01062570.
       Full Text
    • Becker, R. C. “The heparin rebound phenomenon-Does it offer insights toward understanding the pathobiology of coronary thrombosis and its treatment?” Journal of Thrombosis and Thrombolysis 1, no. 2 (1995): 157–61. https://doi.org/10.1007/BF01062573.
       Full Text
    • Becker, R. C. “Cardiac rupture in the thrombolytic era: Is it time to revise the textbooks?” Journal of Thrombosis and Thrombolysis 2, no. 1 (1995): 37–39. https://doi.org/10.1007/BF01063159.
       Full Text
    • Becker, R. C. “Importance of clinical trials in developing safe and effective treatments for acute myocardial infarction: From TIMI II to TIMI 9, GUSTO II, and HIT III.” Journal of Thrombosis and Thrombolysis 2, no. 1 (1995): 29–35. https://doi.org/10.1007/BF01063158.
       Full Text
    • Becker, R. C. “Emerging pharmacological therapy in patients with advanced occlusive peripheral vascular disease.” Vascular Medicine Review 6, no. 3 (1995): 169–74.
    • Becker, R. C. “Exploring the medical need for alternate site testing: A clinician's perspective.” Archives of Pathology and Laboratory Medicine 119, no. 10 (1995): 894–97.
    • Becker, R. C. “Arterial thrombosis for the clinician: Pathobiology and emerging concepts.” Cardiology Clinics 13, no. 3 (1995): 295–310.
    • Becker, R. C. “Coronary thrombolysis in the treatment of women with acute myocardial infarction.” Cardiology 86, no. 4 (1995): 299–303.
    • Becker, R. C. “Education and clinical research issues in women's health.” Cardiology 86, no. 4 (1995): 270–71.
    • Becker, R. C. “Cardiovascular disease in women: Facts and statistics.” Cardiology 86, no. 4 (1995).
    • Becker, R. C. “Editorial: Toward establishing comprehensive universal guidelines for antithrombotic therapy.” Journal of Thrombosis and Thrombolysis 1, no. 3 (1995): 225–29. https://doi.org/10.1007/BF01060731.
       Full Text
    • Becker, R. C. “1995 American College of Cardiology Scientific Session at a glance.” Journal of Thrombosis and Thrombolysis 2, no. 2 (1995): 151–56. https://doi.org/10.1007/BF01064384.
       Full Text
    • Becker, R. C. “Achieving optimal reperfusion without adjunctive antithrombotic therapy: Novel thrombolytic dosing strategies.” Journal of Thrombosis and Thrombolysis 1, no. 3 (1995): 269–77. https://doi.org/10.1007/BF01060736.
       Full Text
    • Becker, R. C. “1994 American Heart Association Scientific Sessions at a Glance.” Journal of Thrombosis and Thrombolysis 2, no. 1 (1995): 71–74. https://doi.org/10.1007/BF01063165.
       Full Text
    • Becker, R. C., A. Charlesworth, R. G. Wilcox, J. Hampton, A. Skene, J. M. Gore, and E. J. Topol. “Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the late assessment of thrombolytic efficacy (LATE) study.” Journal of the American College of Cardiology 25, no. 5 (1995): 1063–68. https://doi.org/10.1016/0735-1097(94)00524-T.
       Full Text
    • Becker, R. C., E. G. Bovill, J. M. Corrao, S. P. Ball, K. Ault, K. G. Mann, and R. P. Tracy. “Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction.” Journal of Thrombosis and Thrombolysis 2, no. 1 (1995): 57–63. https://doi.org/10.1007/BF01063163.
       Full Text
    • Becker, R. C., and J. Ansell. “Antithrombotic therapy: An abbreviated reference for clinicians.” Archives of Internal Medicine 155, no. 2 (1995): 149–61.
    • Meilahn, E. N., R. C. Becker, and J. M. Corrao. “Primary prevention of coronary heart disease in women.” Cardiology 86, no. 4 (1995): 286–98.
    • O’Reilly, R. A., P. Kearns, R. Becker, and J. Ansell. “Intravenous vitamin K₁ injections: Dangerous prophylaxis [1].” Archives of Internal Medicine 155, no. 19 (1995): 2127–28.
    • Velury, V. S., Y. Ma, T. Hurley, J. R. Hebert, C. F. Becker, and R. C. Becker. “Clinical utility of electrocardiographic ST-segment area for predicting unsatisfactory outcomes following thrombolytic therapy.” Journal of Thrombosis and Thrombolysis 2, no. 1 (1995): 51–56. https://doi.org/10.1007/BF01063162.
       Full Text
    • Voyce, S. J., L. I. Heller, B. H. Weiner, L. I. Laifer, L. L. Greenwald, K. T. Carey, and R. C. Becker. “Clinical experience with routine activated coagulation time monitoring during elective PTCA.” Journal of Thrombosis and Thrombolysis 1, no. 2 (1995): 201–6. https://doi.org/10.1007/BF01062579.
       Full Text
    • Becker, R. C. “The emergence of thrombocardiolgy.” Journal of Thrombosis and Thrombolysis 1, no. 1 (1994): 41–43. https://doi.org/10.1007/BF01061994.
       Full Text
    • Becker, R. C. “Beta-adrenergic blockade following thrombolytic therapy: Is it helpful or harmful?” Clinical Cardiology 17, no. 4 (1994): 171–74.
    • Becker, R. C. “Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion.” Clinical Cardiology 17, no. 1 (1994): 3–13.
    • Becker, R. C. “Toward achieving optimal reperfusion: Revisiting thrombolysis.” Coronary Artery Disease 5, no. 8 (1994): 717–22.
    • Becker, R. C. “The thrombin hypothesis: Challenge for the 1990s.” Choices in Cardiology 8, no. 6 (1994): 180–82.
    • Becker, R. C., E. G. Bovill, J. M. Corrao, S. P. Ball, K. Ault, K. Mann, and R. P. Tracy. “Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction.” Journal of Thrombosis and Thrombolysis 1, no. 1 (1994): 95–100. https://doi.org/10.1007/BF01062002.
       Full Text
    • Becker, R. C., J. Cyr, J. M. Corrao, and S. P. Ball. “Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: A coronary care unit experience.” American Heart Journal 128, no. 4 (1994): 719–23. https://doi.org/10.1016/0002-8703(94)90270-4.
       Full Text
    • Becker, R. C., M. Terrin, R. Ross, G. L. Knatterud, P. Desvigne-Nickens, J. M. Gore, and E. Braunwald. “Comparison of clinical outcomes for women and men after acute myocardial infarction.” Annals of Internal Medicine 120, no. 8 (1994): 638–45.
    • Becker, R. C., R. P. Tracy, E. G. Bovill, J. M. Corrao, S. Baker, S. P. Ball, and K. G. Mann. “Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest.” Journal of Thrombosis and Thrombolysis 1, no. 1 (1994): 101–7. https://doi.org/10.1007/BF01062003.
       Full Text
    • Becker, R. C., R. P. Tracy, E. G. Bovill, K. G. Mann, and K. Ault. “The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes.” Coronary Artery Disease 5, no. 4 (1994): 339–45.
    • Becker, R. C., and C. P. Cannon. “Hirudin: Its biology and clinical use.” Journal of Thrombosis and Thrombolysis 1, no. 1 (1994): 7–16. https://doi.org/10.1007/BF01061990.
       Full Text
    • Becker, R. C., and J. Ansell. “Cardiovascular effects of anabolic steroids.” Primary Cardiology 20, no. 3 (1994): 26–27.
    • Cannon, C. P., C. H. McCabe, T. D. Henry, M. J. Schweiger, R. S. Gibson, H. S. Mueller, R. C. Becker, et al. “A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.” Journal of the American College of Cardiology 23, no. 5 (1994): 993–1003.
    • Diaz, M. N., and R. C. Becker. “Anticardiolipin antibodies in patients with unstable angina.” Cardiology 84, no. 6 (1994): 380–84.
    • Greenwald, L., and R. C. Becker. “Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors.” American Heart Journal 128, no. 5 (1994): 997–1009. https://doi.org/10.1016/0002-8703(94)90600-9.
       Full Text
    • Grella, R. D., and R. C. Becker. “Cardiogenic shock complicating coronary artery disease: Diagnosis, treatment, and management.” Current Problems in Cardiology 19, no. 12 (1994): 699–742.
    • Mensah, G. A., R. S. Cooper, Y. Liao, R. C. Becker, M. L. Terrin, and G. Knatterud. “Sex-related outcome differences after acute myocardial infarction [1].” Annals of Internal Medicine 121, no. 10 (1994): 815–16.
    • Sabol, M. B., R. S. Luippold, J. Hebert, S. P. Ball, J. M. Corrao, and R. C. Becker. “Association between serial measures of systemic blood pressure and early coronary arterial perfusion status following intravenous thrombolytic therapy.” Journal of Thrombosis and Thrombolysis 1, no. 1 (1994): 79–84. https://doi.org/10.1007/BF01062000.
       Full Text
    • Alpert, J. S., and R. C. Becker. “Cardiogenic shock: Elements of etiology, diagnosis, and therapy.” Clinical Cardiology 16, no. 3 (1993): 182–90.
    • Alpert, J. S., and R. C. Becker. “Mechanisms and management of cardiogenic shock.” Critical Care Clinics 9, no. 2 (1993): 205–18.
    • Becker, R. C. “The role of blood viscosity in the development and progression of coronary artery disease.” Cleveland Clinic Journal of Medicine 60, no. 5 (1993): 353–58.
    • Becker, R. C. “Thrombolytic agents and anticoagulants.” Cardiovascular Drugs and Therapy 7, no. 5 (1993): 825–28. https://doi.org/10.1007/BF00878937.
       Full Text
    • Becker, R. C. “Thrombolytic therapy: An orchestra without a conductor.” Journal of Intensive Care Medicine 8, no. 2 (1993): 53–55.
    • Becker, R. C. “Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: A theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock.” American Heart Journal 125, no. 3 (1993): 919–29. https://doi.org/10.1016/0002-8703(93)90199-J.
       Full Text
    • Becker, R. C. “Late thrombolytic therapy: Mechanism of benefit and potential risk among patients treated beyond 6 hours.” Coronary Artery Disease 4, no. 3 (1993): 293–304.
    • Becker, R. C. “Antiplatelet therapy in coronary heart disease: Emerging strategies for the treatment and prevention of acute myocardial infarction.” Archives of Pathology and Laboratory Medicine 117, no. 1 (1993): 89–96.
    • Becker, R. C. “Reocclusion following successful thrombolysis. Emerging concepts.” Cardiology 82, no. 4 (1993): 265–73.
    • Becker, R. C., J. M. Corrao, S. P. Ball, and J. M. Gore. “A comparison of heparin strategies after thrombolytic therapy.” American Heart Journal 126, no. 3 PART 1 (1993): 750–52. https://doi.org/10.1016/0002-8703(93)90442-C.
       Full Text
    • Becker, R. C., R. Caputo, S. Ball, J. M. Corrao, S. Baker, and J. M. Gore. “Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration.” American Heart Journal 126, no. 1 (1993): 11–14.
    • Becker, R. C., and J. M. Gore. “The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.” Cardiology 83, no. 1–2 (1993): 100–106.
    • Smyrnios, N. A., M. C. Nitzberg, R. S. Irwin, D. C. Carlucci, C. A. Phillips, R. C. Becker, D. M. Clive, et al. “A 37-year-old woman with altered mental status, fever, and renal failure.” Journal of Intensive Care Medicine 8, no. 6 (1993): 298–309.
    • Voyce, S. J., and R. B. Becker. “Diagnosis, management, and complications of nonpenetrating cardiac trauma: A perspective for practicing clinicians.” Journal of Intensive Care Medicine 8, no. 6 (1993): 275–88.
    • Becker, R. C. “Tools for noninvasive assessment of coronary arterial reperfusion.” Cleveland Clinic Journal of Medicine 59, no. 4 (1992): 403–8.
    • Becker, R. C. “Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians.” American Heart Journal 124, no. 1 (1992): 183–93. https://doi.org/10.1016/0002-8703(92)90939-S.
       Full Text
    • Becker, R. C. “Repeat thrombolysis for early coronary arterial reocclusion.” Coronary Artery Disease 3, no. 6 (1992): 499–512.
    • Becker, R. C. “Thrombin antagonists and antiplatelet agents.” The American Journal of Cardiology 69, no. 2 (1992): A39–51.
    • Becker, R. C. “Seminars in thrombosis, thrombolysis, and vascular biology: 6. Procoagulant states.” Cardiology 80, no. 1 (1992): 51–64.
    • Becker, R. C. “Beta-adrenergic blockade in the thrombolytic era: Editorial comment.” Cardiology 81, no. 1 (1992): 66–68.
    • Becker, R. C., J. M. Corrao, R. Lew, J. Bradley, and J. Queenan. “Relationship between serum total cholesterol, infarct size, and early clinical outcome following acute myocardial infarction.” Cardiology 80, no. 1 (1992): 65–70.
    • Becker, R. C., and J. M. Gore. “Summary.” American Journal of Cardiology 69, no. 2 (1992): 82A.
    • Bovill, E. G., R. Becker, and R. P. Tracy. “Monitoring thrombolytic therapy.” Progress in Cardiovascular Diseases 34, no. 4 (1992): 279–94. https://doi.org/10.1016/0033-0620(92)90022-R.
       Full Text
    • Becker, R. C. “Seminars in thrombosis, thrombolysis, and vascular biology. Part 5: Cellular rheology and plasma viscosity.” Cardiology 79, no. 4 (1991): 265–70.
    • Becker, R. C. “Seminars in thrombosis, thrombolysis and vascular biology. 1. The vascular endothelium.” Cardiology 78, no. 1 (1991): 13–22.
    • Becker, R. C. “Seminars in thrombosis, thrombolysis and vascular biology 4. Fibrinolysis.” Cardiology 79, no. 3 (1991): 188–210.
    • Becker, R. C. “Seminars in thrombosis, thrombolysis, and vascular biology, Part 2: Coagulation and thrombosis.” Cardiology 78, no. 3 (1991): 257–66.
    • Becker, R. C. “Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease.” Cardiology 79, no. 1 (1991): 49–63.
    • Becker, R. C., C. Clyne, B. H. Weiner, R. Lew, S. P. Ball, J. M. Corrao, L. Haugh, R. Tracy, and E. G. Bovill. “Heparin pharmacokinetics and in vitro anticoagulant activity in patients receiving nonionic radiographic contrast media.” Cardiology 79, no. 1 (1991): 31–38.
    • Becker, R. C., J. M. Corrao, R. Harrington, S. P. Ball, and J. M. Gore. “Recombinant tissue-type plasminogen activator: Current concepts and guidelines for clinical use in acute myocardial infarction. Part I.” American Heart Journal 121, no. 1 PART 1 (1991): 220–44. https://doi.org/10.1016/0002-8703(91)90986-R.
       Full Text
    • Becker, R. C., J. M. Corrao, S. P. Ball, V. Klassen, S. P. Baker, and J. Ansell. “The impact of intravascular thrombus formation on hemorrhagic complications following recombinant tissue-type plasminogen activator administration.” Journal of Applied Cardiology 6, no. 5 (1991): 221–27.
    • Becker, R. C., and J. M. Gore. “Adjuvant antiplatelet strategies in coronary thrombolysis.” Circulation 83, no. 3 (1991): 1115–17.
    • Becker, R. C., and J. M. Gore. “Adjunctive use of beta-adrenergic blockers, calcium antagonists and other therapies in coronary thrombolysis.” The American Journal of Cardiology 67, no. 3 (1991): 25–31.
    • Becker, R. C., and J. M. Gore. “Cardiovascular therapies in the 1990s: An overview.” Drugs 41, no. 3 (1991): 345–57.
    • Becker, R. C., and R. Harrington. “Recombinant tissue-type plasminogen activator: Current concepts and guidelines for clinical use in acute myocardial infarction. Part II.” American Heart Journal 121, no. 2 PART 1 (1991): 627–40. https://doi.org/10.1016/0002-8703(91)90746-5.
       Full Text
    • Caputo, R., J. M. Corrao, R. Lew, and R. C. Becker. “Effect of serum total cholesterol on hemorrhagic complications following thrombolytic therapy for acute myocardial infarction.” Cardiology 79, no. 3 (1991): 211–18.
    • Goldberg, R. J., D. Seely, R. C. Becker, J. M. Gore, J. S. Alpert, and J. E. Dalen. “Effect of atrial fibrillation on survival after myocardial infarction.” Primary Cardiology 17, no. 4 (1991): 32-39+64.
    • Goldberg, R. J., D. Seely, R. C. Becker, J. M. Gore, J. S. Alpert, and J. E. Dalen. “Does atrial fibrillation have a serious impact on postinfarction survival?” Cardiology Board Review 8, no. 8 (1991): 51-52+55.
    • Orsinelli, D. A., R. C. Becker, H. F. Cuénoud, and J. M. Moran. “Mechanical failure of a St. Jude Medical prosthesis.” The American Journal of Cardiology 67, no. 9 (1991): 906–8. https://doi.org/10.1016/0002-9149(91)90632-U.
       Full Text
    • Voyce, S. J., and R. C. Becker. “Adaptive and maladaptive cardiovascular responses in human sepsis.” American Heart Journal 122, no. 5 (1991): 1441–48. https://doi.org/10.1016/0002-8703(91)90588-9.
       Full Text
    • Watson, A., R. C. Becker, and J. S. Alpert. “Vasopressin therapy of hemorrhagic complications following coronary artery bypass grafting [4].” Archives of Internal Medicine 151, no. 10 (1991): 2100-.
    • Becker, R. C. “Recombinant t-PA and platelet activity.” Cleveland Clinic Journal of Medicine 57, no. 6 (1990): 537–41.
    • Becker, R. C. “Surgical revascularization in women.” Cardiology 77, no. SUPPL. 2 (1990): 132–39.
    • Becker, R. C. “Introductory article. Clinical highlights and future directions.” Cardiology 77, no. SUPPL. 2 (1990): 1–5.
    • Becker, R. C. “Coronary thrombolysis in women.” Cardiology 77, no. SUPPL. 2 (1990): 110–23.
    • Becker, R. C. “Reperfusion of nonviable myocardium: Lessons from thrombolytic therapy.” Journal of Intensive Care Medicine 5, no. 1 (1990): 1–2.
    • Becker, R. C. “Cardiovascular disease in women. Introductory article. Clinical highlights and future directions.” Cardiology 77 Suppl 2 (1990): 1–5.
    • Becker, R. C., J. M. Corrao, E. G. Bovill, J. M. Gore, S. P. Baker, M. L. Miller, F. V. Lucas, and J. A. Alpert. “Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality.” American Heart Journal 119, no. 6 (1990): 1254–61.
    • Becker, R. C., and J. M. Corrao. “Cardiovascular disease in women: Scope of the problem.” Cardiology 77, no. SUPPL. 2 (1990): 6–7.
    • Becker, R. C., and J. M. Gore. “Tissue plasminogen activator and intracranial hemorrhage.” Annals of Internal Medicine 112, no. 8 (1990): 630-.
    • Becker, R. C., and J. S. Alpert. “The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting.” Archives of Internal Medicine 150, no. 10 (1990): 2016–21. https://doi.org/10.1001/archinte.150.10.2016.
       Full Text
    • Corrao, J. M., R. C. Becker, I. S. Ockene, and G. A. Hamilton. “Coronary heart disease risk factors in women.” Cardiology 77, no. SUPPL. 2 (1990): 8–24.
    • Goldberg, R. J., D. Seeley, R. C. Becker, P. Brady, Z. Chen, V. Osganian, J. M. Gore, J. S. Alpert, and J. E. Dalen. “Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: A community-wide perspective.” American Heart Journal 119, no. 5 (1990): 996–1001. https://doi.org/10.1016/S0002-8703(05)80227-3.
       Full Text
    • Taylor, P., and R. C. Becker. “Noninvasive diagnosis of coronary heart disease in women.” Cardiology 77, no. SUPPL. 2 (1990): 91–98.
    • Becker, R. C., J. M. Gore, and J. S. Alpert. “Postinfarction unstable angina. Pathophysologic basis for current modalities.” Cardiology 76, no. 2 (1989): 144–57.
    • Becker, R. C., and J. M. Corrao. “Circadian variations in cardiovascular disease.” Cleveland Clinic Journal of Medicine 56, no. 7 (1989): 676–80.
    • Becker, R. C., and J. S. Alpert. “Current management of acute myocardial infarction.” Current Problems in Cardiology 14, no. 9 (1989): 501–48.
    • Gore, J. M., M. J. Thompson, and R. C. Becker. “Rapid resolution of acute cor pulmonale with recombinant tissue plasminogen activator.” Chest 96, no. 4 (1989): 939–41.
    • Becker, R. C. “Cardiovascular disease in patients with chronic renal failure.” Cleveland Clinic Journal of Medicine 55, no. 6 (1988): 521–30.
    • Becker, R. C., J. M. Corrao, S. P. Baker, J. M. Gore, and J. S. Alpert. “Circadian variation in thrombolytic response to recombinant tissue-type plasminogen activator in acute myocardial infarction.” Journal of Applied Cardiology 3, no. 3 (1988): 213–21.
    • Becker, R. C., J. M. Corrao, and J. S. Alpert. “Coronary artery bypass surgery in women.” Clinical Cardiology 11, no. 7 (1988): 443–48.
    • Becker, R. C., J. M. Corrao, and J. S. Alpert. “The decision to perform coronary bypass surgery in women. What are the facts?” American Heart Journal 116, no. 3 (1988): 891–93.
    • Becker, R. C., and J. M. Corrao. “Marine omega-3 fatty acids and atherosclerosis.” Annals of Internal Medicine 108, no. 4 (1988): 641-.
    • Becker, R. C., and J. S. Alpert. “Electrocardiographic ST segment depression in coronary heart disease.” American Heart Journal 115, no. 4 (1988): 862–68.
    • Becker, R. C., and J. S. Alpert. “Beyond coronary thrombolysis.” Archives of Internal Medicine 148, no. 7 (1988): 1503–7.
    • Gore, J. M., and R. C. Becker. “Management of post-infarction angina.” Cardiology Clinics 6, no. 1 (1988): 165–72.
    • Becker, R. C., M. Giuliani, R. A. Savage, and J. K. Weick. “Massive hemolysis in clostridium perfringens infections.” Journal of Surgical Oncology 35, no. 1 (1987): 13–18.
    • Becker, R. C., M. Giuliani, and J. S. Alpert. “Nocturnal diaphoresis and coronary artery spasm. Contribution of the parasympathetic nervous system.” Cleveland Clinic Journal of Medicine 54, no. 6 (1987): 515–18.
    • Becker, R. C., P. M. DiBello, and F. V. Lucas. “Bacterial tissue tropism: An in vitro model for infective endocarditis.” Cardiovascular Research 21, no. 11 (1987): 813–20.
    • Becker, R. C., R. G. Martin, and D. A. Underwood. “Right-sided endocardial lesions and flow-directed pulmonary artery catheters.” Cleveland Clinic Journal of Medicine 54, no. 5 (1987): 384–88.
    • Becker, R. C., and D. A. Underwood. “Myocardial infarction in patients undergoing noncardiac surgery.” Cleveland Clinic Journal of Medicine 54, no. 1 (1987): 25–28.
    • Becker, R. C., and J. S. Alpert. “Variant angina pectoris. Is the parasympathetic nervous system at fault?” Chest 92, no. 6 (1987): 963–65.
    • Becker, R. C., and J. S. Alpert. “Nocturnal diaphoresis in Prinzmetal angina.” Annals of Internal Medicine 107, no. 1 (1987): 121-.
    • Lucas, F. V., A. J. Fishleder, R. C. Becker, D. S. Cavalier, and R. R. Tubbs. “Acquired factor X deficiency in systemic amyloidosis.” Cleveland Clinic Journal of Medicine 54, no. 5 (1987): 399–406.
    • Becker, R. C., and R. G. Martin. “Penicillamine-induced insulin antibodies.” Annals of Internal Medicine 104, no. 1 (1986): 127–28.
    • Becker, R. C., J. S. Loeffler, K. A. Leopold, and D. A. Underwood. “Primary tumors of the heart: A review with emphasis on diagnosis and potential treatment modalities.” Seminars in Surgical Oncology 1, no. 4 (1985): 161–70.
    • Becker, R. C., M. Giuliani, and J. K. Weick. “Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus.” Cleveland Clinic Quarterly 52, no. 3 (1985): 409–15.
    • Becker, R. C., R. E. Hobbs, and N. B. Ratliff. “Cardiac rhabdomyosarcoma: Case report with review of clinical and pathologic features.” Cleveland Clinic Quarterly 51, no. 1 (1984): 83–88.
    • Becker, R. C., R. Graor, and J. Holloway. “Pulmonary embolism: A review of 200 cases with emphasis on pathophysiology, diagnosis, and treatment.” Cleveland Clinic Quarterly 51, no. 3 (1984): 519–29.

  • Conference Papers

    • Piccini, J. P., A. S. Hellkamp, Y. Lokhnygina, M. R. Patel, F. E. Harrell, D. E. Singer, R. C. Becker, et al. “Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: Results from the ROCKET AF trial.” In Journal of the American Heart Association, Vol. 3, 2014. https://doi.org/10.1161/JAHA.113.000521.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.